

Clinical Significance of the Cytochrome P450 2C19 Gene

Clinical Pharmacokinetics

41, 913-958

DOI: 10.2165/00003088-200241120-00002

Citation Report

#	ARTICLE	IF	CITATIONS
1	Concordance between proguanil phenotype and CYP2C19 genotype in Chinese. <i>European Journal of Clinical Pharmacology</i> , 2003, 59, 611-614.	0.8	8
2	Allele and genotype frequency of CYP2C19 in a Tamilian population. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 331-333.	1.1	56
3	Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 441-450.	1.1	65
4	Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 653-657.	1.1	98
5	Effect of omeprazole on the steady-state pharmacokinetics of voriconazole. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 56-61.	1.1	93
6	Strategies and Molecular Probes to Investigate the Role of Cytochrome P450 in Drug Metabolism. <i>Clinical Pharmacokinetics</i> , 2003, 42, 153-178.	1.6	115
7	Genetics of Response to Proton Pump Inhibitor Therapy. <i>Molecular Diagnosis and Therapy</i> , 2003, 3, 303-315.	3.3	23
8	Chloramphenicol Is a Potent Inhibitor of Cytochrome P450 Isoforms CYP2C19 and CYP3A4 in Human Liver Microsomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3464-3469.	1.4	40
9	Non-variceal upper gastrointestinal haemorrhage. <i>Gut</i> , 2003, 52, 609-609.	6.1	2
10	Pharmacogenomics in the treatment of epilepsy. <i>Pharmacogenomics</i> , 2003, 4, 747-751.	0.6	10
11	An Overview of Proton Pump Inhibitors. <i>Gastroenterology Nursing</i> , 2003, 26, 182-190.	0.2	37
12	Sequence diversity and functional characterization of the 5'??-regulatory region of human CYP2C19. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 199-206.	5.7	14
13	Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes. <i>Pharmacogenomics</i> , 2004, 5, 673-689.	0.6	8
14	Drug pathways: moving beyond single gene pharmacogenetics. <i>Pharmacogenomics</i> , 2004, 5, 139-141.	0.6	20
15	Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1083-1105.	1.0	193
16	From The Cover: Gnotobiotic zebrafish reveal evolutionarily conserved responses to the gut microbiota. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 4596-4601.	3.3	840
17	Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. <i>European Journal of Endocrinology</i> , 2004, 150, 299-303.	1.9	98
18	Lansoprazoleâ€™Tacrolimus Interaction in Japanese Transplant Recipient with CYP2C19 Polymorphism. <i>Annals of Pharmacotherapy</i> , 2004, 38, 791-794.	0.9	36

#	ARTICLE	IF	CITATIONS
19	Genetic polymorphism of cytochrome P450 2C19 in healthy Malaysian subjects. <i>British Journal of Clinical Pharmacology</i> , 2004, 58, 332-335.	1.1	44
20	Review article: relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 11-19.	1.9	62
21	Impact of inter-individual differences in drug metabolism and pharmacokinetics on safety evaluation. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 609-620.	1.0	38
22	CYP2C19 Polymorphism and Proton Pump Inhibitors. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2004, 95, 2-8.	1.2	138
23	Omeprazole as a CYP2C19 Marker in Chinese Subjects: Assessment of Its Gene-Dose Effect and Intrasubject Variability. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 582-589.	1.0	49
24	Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 2202-2210.	6.7	149
25	Stereoselective metabolism of methadone N-demethylation by cytochrome P450 2B6 and 2C19. <i>Chirality</i> , 2004, 16, 36-44.	1.3	234
26	St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 191-197.	2.3	123
27	CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 201-209.	2.3	93
28	Flow Cytometric Assay for Genotyping Cytochrome P450 2C9 and 2C19. <i>Molecular Diagnosis and Therapy</i> , 2004, 4, 199-207.	3.3	21
29	The Metabolic Fate of Amitriptyline, Nortriptyline and Amitriptylinoxide in Man. <i>Drug Metabolism Reviews</i> , 2004, 36, 723-746.	1.5	74
30	Genetic Polymorphisms of Cytochrome P450 Enzymes and the Effect on Interindividual, Pharmacokinetic Variability in Extensive Metabolizers. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 447-456.	1.0	16
31	Charge and Substituent Effects on Affinity and Metabolism of Benzbromarone-Based CYP2C19 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 6768-6776.	2.9	34
32	Pharmacogenetics. <i>Primary Care - Clinics in Office Practice</i> , 2004, 31, 543-559.	0.7	6
33	Applications of genotyping and phenotyping for clinically-relevant polymorphisms of drug metabolizing enzymes and drug transporters. <i>Handbook of Analytical Separations</i> , 2004, , 321-353.	0.8	3
34	Genetic Predictors of the Clinical Response to Opioid Analgesics. <i>Clinical Pharmacokinetics</i> , 2004, 43, 983-1013.	1.6	230
35	QT Prolongation with Antimicrobial Agents. <i>Drugs</i> , 2004, 64, 1091-1124.	4.9	114
36	Therapeutic drug monitoring of old and newer anti-epileptic drugs. <i>Clinical Chemistry and Laboratory Medicine</i> , 2004, 42, 1228-55.	1.4	147

#	ARTICLE	IF	CITATIONS
37	Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles. <i>Cancer Research</i> , 2004, 64, 5804-5811.	0.4	222
38	From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. <i>Pharmacogenomics</i> , 2004, 5, 571-579.	0.6	111
39	Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. <i>Trends in Pharmacological Sciences</i> , 2004, 25, 193-200.	4.0	579
40	Technology platforms for pharmacogenomic diagnostic assays. <i>Nature Reviews Drug Discovery</i> , 2004, 3, 749-761.	21.5	86
41	Variability in Cytochrome P450-Mediated Metabolism of Cardiovascular Drugs: Clinical Implications and Practical Attempts to Avoid Potential Problems. <i>Cardiology</i> , 2004, 4, 55-79.	0.3	6
42	Pharmacogenetics and herb???drug interactions. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 841-850.	5.7	168
43	Gastroesophageal Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 390-402.	1.1	28
44	Induction of Testosterone Metabolism by Esomeprazole in a CYP2C19*2 Heterozygote. <i>American Journal of the Medical Sciences</i> , 2004, 327, 289-293.	0.4	13
45	In Vivo Metabolic Activity of CYP2C19 and CYP3A in Relation to CYP2C19 Genetic Polymorphism in Chronic Liver Disease. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1221-1229.	1.0	40
47	Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 25-33.	2.3	130
48	, but not , polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 370-377.	2.3	51
49	Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 78, 559-581.	2.3	110
50	Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: an investigative and comparative study. <i>European Journal of Clinical Pharmacology</i> , 2005, 61, 179-184.	0.8	86
51	Single Nucleotide Polymorphisms (SNPs): History, Biotechnological Outlook and Practical Applications. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2005, 3, 237-245.	0.3	12
52	Cytochrome P450 gene-based drug prescribing and factors impacting translation into routine clinical practice. <i>Personalized Medicine</i> , 2005, 2, 213-224.	0.8	11
53	Defining and Searching Pharmacogenetics and Pharmacogenomics to Identify Its Core Research Journals. <i>Science and Technology Libraries</i> , 2005, 26, 69-88.	0.8	4
54	SERTRALINE IS METABOLIZED BY MULTIPLE CYTOCHROME P450 ENZYMES, MONOAMINE OXIDASES, AND GLUCURONYL TRANSFERASES IN HUMAN: AN IN VITRO STUDY. <i>Drug Metabolism and Disposition</i> , 2005, 33, 262-270.	1.7	202
55	Human Cytochrome P450 Enzymes. , 2005, , 377-530.		203

#	ARTICLE	IF	CITATIONS
56	Sex and Racial Differences in Pharmacological Response: Where Is the Evidence? Pharmacogenetics, Pharmacokinetics, and Pharmacodynamics. <i>Journal of Women's Health</i> , 2005, 14, 19-29.	1.5	250
57	Metabolism and Transport of Oxazaphosphorines and the Clinical Implications. <i>Drug Metabolism Reviews</i> , 2005, 37, 611-703.	1.5	158
58	Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality?. <i>Pharmacogenomics</i> , 2005, 6, 701-711.	0.6	11
59	Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance. <i>Drug Metabolism Reviews</i> , 2005, 37, 41-213.	1.5	257
60	The Effect of Aging on the Relationship between the Cytochrome P450 2C19 Genotype and Omeprazole Pharmacokinetics. <i>Clinical Pharmacokinetics</i> , 2005, 44, 1179-1189.	1.6	60
61	Further Evidence for Interethnic Differences in the Oral Pharmacokinetics of Meloxicam. <i>Clinical Drug Investigation</i> , 2005, 25, 307-313.	1.1	9
62	Ontogeny of drug metabolizing enzymes in the neonate. <i>Seminars in Fetal and Neonatal Medicine</i> , 2005, 10, 123-138.	1.1	161
63	Cytochrome P450 Polymorphisms in Geriatric Patients. <i>Drugs and Aging</i> , 2005, 22, 265-272.	1.3	15
64	Voriconazole Therapeutic Drug Monitoring. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1570-1572.	1.4	383
65	Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19. <i>Psychosomatics</i> , 2006, 47, 75-85.	2.5	270
66	The AmpliChip CYP450 Test: Principles, Challenges, and Future Clinical Utility in Digestive Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 822-830.	2.4	22
67	Ethnic or Racial Differences Revisited. <i>Clinical Pharmacokinetics</i> , 2006, 45, 957-964.	1.6	118
69	Clinical pharmacokinetics of voriconazole. <i>International Journal of Antimicrobial Agents</i> , 2006, 27, 274-284.	1.1	129
70	Genetic testing for pharmacogenetics and its clinical application in drug therapy. <i>Clinica Chimica Acta</i> , 2006, 363, 177-186.	0.5	38
71	AmpliChip for Cytochrome P-450 Genotyping: The Epoch of Personalized Prescriptions. <i>Hospital Pharmacy</i> , 2006, 41, 442-454.	0.4	2
73	Phenotype-genotype Relationship and Clinical Effects of Citalopram in Chinese Patients. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 367-372.	0.7	43
74	Heterozygous Mutation in CYP2C19 Significantly Increases the Concentration/Dose Ratio of Racemic Citalopram and Escitalopram (S-citalopram). <i>Therapeutic Drug Monitoring</i> , 2006, 28, 102-105.	1.0	49
75	Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay). <i>BMC Clinical Pharmacology</i> , 2006, 6, 8.	2.5	7

#	ARTICLE	IF	CITATIONS
76	Enantioselective disposition of rabeprazole in relation to CYP2C19 genotypes. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 315-320.	1.1	31
77	Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. <i>Nature Reviews Cancer</i> , 2006, 6, 886-893.	12.8	69
78	Cytochrome P450 pharmacogenetics and cancer. <i>Oncogene</i> , 2006, 25, 1679-1691.	2.6	492
79	A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 103-113.	2.3	620
80	Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 80, 126-135.	2.3	143
81	Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. <i>Epilepsy Research</i> , 2006, 71, 54-63.	0.8	23
82	Pharmacogenomics and Individualized Drug Therapy. <i>Annual Review of Medicine</i> , 2006, 57, 119-137.	5.0	576
84	Update on pharmacogenetics in epilepsy: a brief review. <i>Lancet Neurology</i> , The, 2006, 5, 189-196.	4.9	70
85	Individualizing analgesic prescription. Part II: pharmacogenetics of anti-inflammatory analgesics and co-analgesics. <i>Personalized Medicine</i> , 2006, 3, 271-297.	0.8	4
86	Clinical Pharmacology of Cyclophosphamide and Ifosfamide. <i>Current Drug Therapy</i> , 2006, 1, 55-84.	0.2	83
87	CYP2C19 Genetic Polymorphism in Thai, Burmese and Karen Populations. <i>Drug Metabolism and Pharmacokinetics</i> , 2006, 21, 286-290.	1.1	33
88	Laboratory Investigation of Vitamin B ₁₂ Deficiency. <i>Laboratory Medicine</i> , 2006, 37, 166-174.	0.8	8
89	Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice. <i>Pharmacological Reviews</i> , 2006, 58, 521-590.	7.1	379
90	Antimicrobial-Associated QT Interval Prolongation: Pointes of Interest. <i>Clinical Infectious Diseases</i> , 2006, 43, 1603-1611.	2.9	199
91	CYP2C19 Polymorphism and Risk for Essential Tremor. <i>European Neurology</i> , 2006, 56, 119-123.	0.6	29
92	Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy. <i>Clinical Microbiology Reviews</i> , 2006, 19, 763-787.	5.7	35
93	High-Throughput Radiometric CYP2C19 Inhibition Assay Using Tritiated (S)-Mephenytoin. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1737-1743.	1.7	14
94	Pharmacogenetics of the Cytochrome P450 Enzyme System: Review of Current Knowledge and Clinical Significance. <i>Journal of Pharmacy Practice</i> , 2007, 20, 206-218.	0.5	32

#	ARTICLE	IF	CITATIONS
95	Antifungal serum concentration monitoring: an update. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 17-25.	1.3	122
96	<i>Clinical Pharmacogenetics.</i> , 2007, , 179-195.		2
97	Distinct Effects of Omeprazole and Rabeprazole on the Tacrolimus Blood Concentration in a Kidney Transplant Recipient. <i>Drug Metabolism and Pharmacokinetics</i> , 2007, 22, 441-444.	1.1	24
98	Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. <i>Pharmacogenetics and Genomics</i> , 2007, 17, 431-445.	0.7	117
99	Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. <i>Anti-Cancer Drugs</i> , 2007, 18, 111-126.	0.7	71
100	3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. <i>Biochemical and Biophysical Research Communications</i> , 2007, 355, 513-519.	1.0	112
101	Identifying drugs needing pharmacogenetic monitoring in a Korean hospital. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 166-175.	0.5	15
102	Gynaecomastia Associated with Proton Pump Inhibitors. <i>Drug Safety</i> , 2007, 30, 527-531.	1.4	22
103	The Role of Pharmacogenetics in the Metabolism of Antiepileptic Drugs. <i>Clinical Pharmacokinetics</i> , 2007, 46, 271-279.	1.6	109
104	The Clinical Pharmacokinetics of Escitalopram. <i>Clinical Pharmacokinetics</i> , 2007, 46, 281-290.	1.6	183
105	Influence of Cytochrome P450 (CYP) 3A5 Polymorphisms on the Pharmacokinetics of Lansoprazole Enantiomers in CYP2C19 Extensive Metaboliser Renal Transplant Recipients. <i>Clinical Drug Investigation</i> , 2007, 27, 251-258.	1.1	7
106	Are All Proton Pump Inhibitors Created Equal?. <i>Gastroenterology</i> , 2007, 132, 1622-1624.	0.6	1
107	Cytochrome P450 reaction-phenotyping: an industrial perspective. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 667-687.	1.5	117
108	<i>Factors Influencing Drug Metabolism.</i> , 2007, , 1-18.		1
109	Stereoselective hexobarbital 3- α -hydroxylation by CYP2C19 expressed in yeast cells and the roles of amino acid residues at positions 300 and 476. <i>Chirality</i> , 2007, 19, 550-558.	1.3	4
110	Association between cytochrome P450 (CYP) 2C19 polymorphisms and harm avoidance in Japanese. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2007, 144B, 724-727.	1.1	19
111	Interactions métaboliques des antifongiques azolés. <i>Journal De Mycologie Medicale</i> , 2007, 17, 168-176.	0.7	8
112	Phenotype-genotype analysis of CYP2C19 in Colombian mestizo individuals. <i>BMC Clinical Pharmacology</i> , 2007, 7, 6.	2.5	34

#	ARTICLE	IF	CITATIONS
113	Enhancing Race-Based Prescribing Precision with Pharmacogenomics. <i>Clinical Pharmacology and Therapeutics</i> , 2007, 81, 323-325.	2.3	8
114	Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 517-524.	0.7	30
115	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. <i>British Journal of Clinical Pharmacology</i> , 2007, 64, 67-74.	1.1	55
116	Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 419-426.	1.0	106
117	Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2429-2436.	1.9	668
118	Herbal medicine Yin Zhi Huang induces CYP3A4-mediated sulfoxidation and CYP2C19-dependent hydroxylation of omeprazole. <i>Acta Pharmacologica Sinica</i> , 2007, 28, 1685-1692.	2.8	17
119	Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, 116, 496-526.		990
120	CYP2C19 Polymorphism in Korean patients on warfarin therapy. <i>Archives of Pharmacal Research</i> , 2007, 30, 344-349.	2.7	18
121	Estimation of CYP2C19 activity by the omeprazole hydroxylation index at a single point in time after intravenous and oral administration. <i>European Journal of Clinical Pharmacology</i> , 2007, 63, 1031-1038.	0.8	17
122	Metabolism of N-Methyl, N-propargylphenylethylamine: Studies with Human Liver Microsomes and cDNA Expressed Cytochrome P450 (CYP) Enzymes. <i>Cellular and Molecular Neurobiology</i> , 2007, 27, 179-190.	1.7	6
123	Inhibition and induction of human cytochrome P450 enzymes: current status. <i>Archives of Toxicology</i> , 2008, 82, 667-715.	1.9	481
124	Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. <i>Analytical and Bioanalytical Chemistry</i> , 2008, 392, 1093-1108.	1.9	510
125	Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 387-398.	0.8	8
126	Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 1181-1188.	0.8	73
127	Proton pump inhibitors: an update of their clinical use and pharmacokinetics. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 935-951.	0.8	266
128	Pharmacokinetic considerations for the use of newer antifungal agents. <i>Current Fungal Infection Reports</i> , 2008, 2, 5-11.	0.9	0
129	The Effect of CYP2C19 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Clopidogrel: A Possible Mechanism for Clopidogrel Resistance. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 236-242.	2.3	270
130	CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype. <i>British Journal of Cancer</i> , 2008, 99, 1251-1255.	2.9	46

#	ARTICLE	IF	CITATIONS
131	Defining drug disposition determinants: a pharmacogeneticâ€“pharmacokinetic strategy. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 293-305.	21.5	38
132	Creating and evaluating genetic tests predictive of drug response. <i>Nature Reviews Drug Discovery</i> , 2008, 7, 568-574.	21.5	51
133	Impact of the Ultrarapid CYP2C19*17 Allele on Serum Concentration of Escitalopram in Psychiatric Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 322-327.	2.3	195
134	Limited frequency of the CYP2C19*17 allele and its minor role in a Japanese population. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 437-439.	1.1	99
135	Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2008, 65, 767-774.	1.1	129
136	Pharmacogenomics Applications in Drug Metabolism. <i>Methods in Pharmacology and Toxicology</i> , 2008, , 109-120.	0.1	0
137	Pharmacokinetics, Safety and Tolerance of Voriconazole in Renally??Impaired Subjects. <i>Clinical Drug Investigation</i> , 2008, 28, 409-420.	1.1	49
138	Sex-specific differences in CYP450 isoforms in humans. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 413-424.	1.5	137
139	Cytochrome P450 Enzyme Polymorphism Frequency in Indigenous and Native American Populations: A Systematic Review. <i>Public Health Genomics</i> , 2008, 11, 141-149.	0.6	36
140	PhRMA White Paper on ADME Pharmacogenomics. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 849-889.	1.0	62
141	Cytochrome P450s in the development of target-based anticancer drugs. <i>Cancer Letters</i> , 2008, 259, 1-15.	3.2	53
142	Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. <i>Clinica Chimica Acta</i> , 2008, 391, 60-67.	0.5	35
143	Pharmacogenetics: From Description to Prediction. <i>Clinics in Laboratory Medicine</i> , 2008, 28, 499-511.	0.7	7
144	Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes. <i>Pharmacoeconomics</i> , 2008, 26, 569-587.	1.7	75
145	Clinical applications of pharmacogenomics to adverse drug reactions. <i>Expert Review of Clinical Pharmacology</i> , 2008, 1, 251-260.	1.3	6
146	Misclassification of Allele CYP2C19*10 as CY2C19*2 by a Commonly Used PCR-RFLP Procedure. <i>Genetic Testing and Molecular Biomarkers</i> , 2008, 12, 57-58.	1.7	3
147	Regulatory Polymorphisms and their Contribution to Interindividual Differences in the Expression of Enzymes Influencing Drug and Toxicant Disposition. <i>Drug Metabolism Reviews</i> , 2008, 40, 263-301.	1.5	20
148	Pantoprazole: from drug metabolism to clinical relevance. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 471-483.	1.5	13

#	ARTICLE	IF	CITATIONS
149	CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. <i>Pharmacogenomics</i> , 2008, 9, 1251-1259.	0.6	209
150	Role of Specific Cytochrome P450 Isoforms in the Conversion of Phenoxypropoxybiguanide Analogs in Human Liver Microsomes to Potent Antimalarial Dihydrotriazines. <i>Drug Metabolism and Disposition</i> , 2008, 36, 380-385.	1.7	13
151	Pharmacogenetics of analgesics: toward the individualization of prescription. <i>Pharmacogenomics</i> , 2008, 9, 905-933.	0.6	91
153	High-Throughput Protein-Based Technologies and Computational Models for Drug Development, Efficacy, and Toxicity. , 0, , 29-52.		4
154	A high incidence of polymorphic CYP2C19 variants in archival blood samples from Papua New Guinea. <i>Human Genomics</i> , 2008, 3, 17.	1.4	15
155	Therapeutic Drug Monitoring of Voriconazole. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 403-411.	1.0	116
156	Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5,) Tj ETQq0 0 0 rgBT /Overlock 4-hydroxycyclophosphamide. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 515-523.	0.7	111
157	Cytochrome P450 Part 2: Genetics of Interâ€Individual Variability. <i>Journal of Pharmacy Practice and Research</i> , 2008, 38, 226-229.	0.5	2
158	Therapeutic drug monitoring for triazoles. <i>Current Opinion in Infectious Diseases</i> , 2008, 21, 580-586.	1.3	128
159	Race as a variable in pharmacogenomics science: from empirical ethics to publication standards. <i>Pharmacogenetics and Genomics</i> , 2008, 18, 837-841.	0.7	6
160	Pharmacogenetics of Drug Metabolism. , 2009, , 301-317.		2
161	Proton Pump Inhibitors and Clopidogrel â€“ Hazardous Drug Interaction or Hazardous Interpretation of Data?. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2009, 23, 251-252.	1.8	17
162	Effects of Standard and Supratherapeutic Doses of Nelfinavir on Cardiac Repolarization: A Thorough QT Study. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 291-300.	1.0	18
163	Are Atlantic Cod in Store LungegÃ¥rdsvann, a Seawater Recipient in Bergen, Affected by Environmental Contaminants? A qRT-PCR Survey. <i>Journal of Toxicology and Environmental Health - Part A: Current Issues</i> , 2009, 72, 140-154.	1.1	14
164	Pharmacogenomics of Tamoxifen Therapy. <i>Clinical Chemistry</i> , 2009, 55, 1770-1782.	1.5	142
165	Clopidogrel Inhibits CYP2C19â€Dependent Hydroxylation of Omeprazole Related to CYP2C19 Genetic Polymorphisms. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 574-581.	1.0	39
166	Personalized medicine and antiplatelet therapy: ready for prime time?. <i>European Heart Journal</i> , 2009, 30, 1943-1963.	1.0	37
167	Identification of New<i>CYP2C19</i> Variants Exhibiting Decreased Enzyme Activity in the Metabolism of<i>S</i>-Mephenytoin and Omeprazole. <i>Drug Metabolism and Disposition</i> , 2009, 37, 2262-2269.	1.7	38

#	ARTICLE	IF	CITATIONS
168	A Bioinformatics Approach for the Phenotype Prediction of Nonsynonymous Single Nucleotide Polymorphisms in Human Cytochromes P450. <i>Drug Metabolism and Disposition</i> , 2009, 37, 977-991.	1.7	42
169	Clinical pharmacology, biomarkers and personalized medicine: education please. <i>Biomarkers in Medicine</i> , 2009, 3, 685-700.	0.6	9
170	Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. <i>Pharmacogenomics</i> , 2009, 10, 435-449.	0.6	21
171	Rapid Identification of the Hepatic Cytochrome P450 2C19 Activity Using a Novel and Noninvasive [¹³ C]Pantoprazole Breath Test. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 329, 297-305.	1.3	36
172	Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 541-551.	1.4	117
173	Clopidogrel: With or Without a Proton Pump Inhibitor?. <i>Geriatric Nursing</i> , 2009, 30, 188-192.	0.9	3
174	Cytochrome P ₄₅₀ -dependent toxicity of dapsone in human erythrocytes. <i>Journal of Applied Toxicology</i> , 2010, 30, 271-275.	1.4	26
175	Influence of number of calibration standards within a defined range on pharmacokinetic disposition—case studies with omeprazole and clopidogrel carboxylic acid. <i>Biomedical Chromatography</i> , 2010, 24, 544-549.	0.8	3
176	Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy—Does structural design, dosing and induction strategies have a role to play?. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2009, 34, 147-150.	0.6	4
177	Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH. <i>European Journal of Clinical Pharmacology</i> , 2009, 65, 19-31.	0.8	204
178	Population pharmacokinetics of intravenous pantoprazole in paediatric intensive care patients. <i>British Journal of Clinical Pharmacology</i> , 2009, 67, 216-227.	1.1	18
179	Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 682-689.	1.1	9
180	Association of CYP2B6, CYP3A5, and CYP2C19 Genetic Polymorphisms With Sibutramine Pharmacokinetics in Healthy Korean Subjects. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 511-518.	2.3	19
181	CYP2D6 and tamoxifen: DNA matters in breast cancer. <i>Nature Reviews Cancer</i> , 2009, 9, 576-586.	12.8	287
182	Trade Herbal Products and Induction of CYP2C19 and CYP2E1 in Cultured Human Hepatocytes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 105, 58-63.	1.2	32
183	Pharmacokinetics of Phenytoin: Reminders and Discoveries. <i>Epilepsy Currents</i> , 2009, 9, 102-104.	0.4	11
184	The CYP2C19*2 and CYP2C19*3 polymorphisms are associated with high post-treatment platelet reactivity in Asian patients with acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 897-899.	1.9	44
185	The clinical impact of pharmacogenetics on the treatment of epilepsy. <i>Epilepsia</i> , 2009, 50, 1-23.	2.6	226

#	ARTICLE	IF	CITATIONS
186	Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1266-1274.	0.9	101
187	Polymorphism of human cytochrome P450 enzymes and its clinical impact. <i>Drug Metabolism Reviews</i> , 2009, 41, 89-295.	1.5	671
188	Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections. <i>Expert Review of Hematology</i> , 2009, 2, 237-254.	1.0	28
189	Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , 2009, 48, 199-209.	1.6	37
190	Need for reassessment of reported CYP2C19 allele frequencies in various populations in view of CYP2C19*17 discovery: the case of Greece. <i>Pharmacogenomics</i> , 2009, 10, 43-49.	0.6	62
191	Pharmacogenomics of anticoagulants: steps toward personal dosage. <i>Genome Medicine</i> , 2009, 1, 10.	3.6	33
192	Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. <i>European Heart Journal</i> , 2009, 30, 1744-1752.	1.0	231
193	Genetic Polymorphism of Metabolic Enzymes P450 (CYP) as a Susceptibility Factor for Drug Response, Toxicity, and Cancer Risk. <i>Arhiv Za Higijenu Rada I Toksikologiju</i> , 2009, 60, 217-242.	0.4	147
194	Impact of rat P450 genetic polymorphism on diazepam metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 1421-1433.	1.5	14
195	Ethnic differences in drug metabolism and toxicity from chemotherapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 243-257.	1.5	106
196	Cytochrome P-450 Polymorphisms and Response to Clopidogrel. <i>New England Journal of Medicine</i> , 2009, 360, 354-362.	13.9	2,209
197	Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. <i>Pharmacogenomics</i> , 2009, 10, 1799-1817.	0.6	100
198	Hallucinations During Voriconazole Therapy: Who Is at Higher Risk and Could Benefit From Therapeutic Drug Monitoring?. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 135-136.	1.0	4
200	DNA Microarray Technology in the Clinical Environment: The AmpliChip CYP450 Test for CYP2D6 and CYP2C19 Genotyping. <i>CNS Spectrums</i> , 2009, 14, 19-35.	0.7	84
201	Impact of CYP2C19 Polymorphisms on the Antiplatelet Effect of Clopidogrel in an Actual Clinical Setting in Japan. <i>Circulation Journal</i> , 2009, 73, 1498-1503.	0.7	85
202	Genetic Variations and Haplotypes of the 5' Regulatory Region of CYP2C19 in South Indian Population. <i>Drug Metabolism and Pharmacokinetics</i> , 2009, 24, 185-193.	1.1	11
203	Influence of the Genetic Polymorphisms in the 5' Flanking and Exonic Regions of CYP2C19 on Proguanil Oxidation. <i>Drug Metabolism and Pharmacokinetics</i> , 2009, 24, 537-548.	1.1	12
204	Clopidogrel Pharmacogenetics and Its Clinical Implications. <i>American Journal of Therapeutics</i> , 2010, 17, e66-e73.	0.5	6

#	ARTICLE	IF	CITATIONS
205	Does Black Ethnicity Influence the Development of Stent Thrombosis in the Drug-Eluting Stent Era?. <i>Circulation</i> , 2010, 122, 1085-1090.	1.6	46
206	Genetic predisposition to adverse drug reactions in the intensive care unit. <i>Critical Care Medicine</i> , 2010, 38, S106-S116.	0.4	52
207	Clopidogrel Resistance. <i>American Journal of Therapeutics</i> , 2010, 17, 210-215.	0.5	24
208	Factors associated with clopidogrel nonresponsiveness. <i>Future Cardiology</i> , 2010, 6, 195-210.	0.5	10
209	The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 145-151.	0.8	23
210	Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 563-569.	0.8	19
211	Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1005-1015.	0.8	10
212	Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 1165-1169.	0.8	7
214	Antifungal Therapeutic Drug Monitoring. <i>Current Fungal Infection Reports</i> , 2010, 4, 158-167.	0.9	24
215	The Role of Second-Generation Antifungal Triazoles for Treatment of the Endemic Mycoses. <i>Current Infectious Disease Reports</i> , 2010, 12, 471-478.	1.3	7
216	Benefits of Pharmacogenomics in Drug Development—Earlier Launch of Drugs and Less Adverse Events. <i>Journal of Medical Systems</i> , 2010, 34, 701-707.	2.2	8
217	Effect of cytochrome P450 polymorphism on arachidonic acid metabolism and their impact on cardiovascular diseases. , 2010, 125, 446-463.		154
218	Genetic Causes of Clopidogrel Nonresponsiveness: Which Ones Really Count?. <i>Pharmacotherapy</i> , 2010, 30, 265-274.	1.2	41
219	Impact of Proton Pump Inhibitors on the Effectiveness of Clopidogrel After Coronary Stent Placement: The Clopidogrel Medco Outcomes Study. <i>Pharmacotherapy</i> , 2010, 30, 787-796.	1.2	111
220	Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. <i>European Journal of Pharmacology</i> , 2010, 626, 200-204.	1.7	43
221	The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: A cross-sectional study in Iran. <i>Clinical Therapeutics</i> , 2010, 32, 1050-1060.	1.1	41
222	Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature. <i>Drug Development Research</i> , 2010, 71, 492-501.	1.4	24
223	Association between CYP2C19 polymorphism and depressive symptoms. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1160-1166.	1.1	35

#	ARTICLE	IF	CITATIONS
224	Clustering of malaria treatment failure (TF) in Daraweesh: Hints for host genetic susceptibility to TF with emphasis on immune-modulating SNPs. <i>Infection, Genetics and Evolution</i> , 2010, 10, 481-486.	1.0	3
225	Genotype Frequencies of Selected Drug Metabolizing Enzymes and ABC Drug Transporters among Breast Cancer Patients on FAC Chemotherapy. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 107, 570-576.	1.2	16
226	Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17. <i>British Journal of Clinical Pharmacology</i> , 2010, 69, 222-230.	1.1	213
227	Antiplatelet drug interactions. <i>Journal of Internal Medicine</i> , 2010, 268, 516-529.	2.7	39
228	Assessment of CYP2C19 genetic polymorphisms in a Korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 697-703.	0.7	50
229	Pharmacogenetics of esomeprazole or rabeprazole-based triple therapy in <i>Helicobacter pylori</i> eradication in Hong Kong non-ulcer dyspepsia Chinese subjects. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 343-350.	0.7	26
230	Cytochrome P450 CYP2C19 genotypes in Nigerian sickle-cell disease patients and normal controls. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, no-no.	0.7	5
231	Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2010, 35, 351-360.	0.7	24
232	Proton Pump Inhibitor and Clopidogrel Interaction: Fact or Fiction?. <i>American Journal of Gastroenterology</i> , 2010, 105, 34-41.	0.2	119
233	Antiplatelet agents and proton pump inhibitors – personalizing treatment. <i>Pharmacogenomics and Personalized Medicine</i> , 2010, 3, 101.	0.4	1
234	Implications of Inter-Individual Differences in Clopidogrel Metabolism, with Focus on Pharmacogenetics. <i>Pharmaceuticals</i> , 2010, 3, 782-794.	1.7	7
235	Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China. <i>Genetics and Molecular Research</i> , 2010, 9, 1844-1851.	0.3	32
236	Introduction to pharmacokinetics and pharmacodynamics. , 0, , 35-54.		0
237	Review Article: Combination of Clopidogrel and Proton Pump Inhibitors: Implications for Clinicians. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2010, 15, 326-337.	1.0	18
238	Clopidogrel in acute coronary syndrome: implications of recent study findings. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 1215-1229.	0.6	2
239	Comparative Effectiveness And Personalized Medicine: Evolving Together Or Apart?. <i>Health Affairs</i> , 2010, 29, 1783-1787.	2.5	17
240	CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. <i>European Heart Journal</i> , 2010, 31, 3046-3053.	1.0	138
241	<i>CYP2C9</i>*1B</i> Promoter Polymorphisms, in Linkage with <i>CYP2C19</i>*2</i>, Affect Phenytoin Autoinduction of Clearance and Maintenance Dose. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 332, 599-611.	1.3	50

#	ARTICLE	IF	CITATIONS
242	Regulation of CYP2C19 Expression by Estrogen Receptor α : Implications for Estrogen-Dependent Inhibition of Drug Metabolism. <i>Molecular Pharmacology</i> , 2010, 78, 886-894.	1.0	53
243	Voriconazole Pharmacokinetics in Liver Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 852-859.	1.4	36
244	Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 393-407.	1.5	20
245	<i>Aspergillus niger</i> : an unusual cause of invasive pulmonary aspergillosis. <i>Journal of Medical Microbiology</i> , 2010, 59, 834-838.	0.7	115
246	Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 1821.	3.8	980
247	Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. <i>Current Medical Research and Opinion</i> , 2010, 26, 2077-2085.	0.9	8
248	Single time point diagnostic breath tests: a review. <i>Journal of Breath Research</i> , 2010, 4, 017002.	1.5	21
249	Cost Effectiveness of Pharmacogenomics. <i>Pharmacoeconomics</i> , 2010, 28, 1001-1013.	1.7	94
250	Using sweeping-micellar electrokinetic chromatography to determine voriconazole in patient plasma. <i>Talanta</i> , 2010, 82, 653-659.	2.9	17
251	Proton Pump Inhibitors and Clopidogrel. <i>Cardiovascular Therapeutics</i> , 2010, 28, 169-176.	1.1	2
252	Metabolic Barrier of the Gastrointestinal Tract*. , 2010, , 53-75.		2
253	Pharmacogenetics and human genetic polymorphisms. <i>Biochemical Journal</i> , 2010, 429, 435-449.	1.7	91
254	Comparative Effectiveness Research and Personalized Medicine. <i>Pharmacoeconomics</i> , 2010, 28, 905-913.	1.7	40
255	Triazole Antifungal Agents in Invasive Fungal Infections. <i>Drugs</i> , 2011, 71, 2405-2419.	4.9	217
256	Current Concepts in Antifungal Pharmacology. <i>Mayo Clinic Proceedings</i> , 2011, 86, 805-817.	1.4	305
257	High-resolution melting curve analysis to establish CYP2C19 [∗] 2 single nucleotide polymorphism: Comparison with hydrolysis SNP analysis. <i>Molecular and Cellular Probes</i> , 2011, 25, 130-133.	0.9	8
258	Pharmacogenomics of clopidogrel: Evidence and perspectives. <i>Thrombosis Research</i> , 2011, 128, 307-316.	0.8	76
259	Novel drug metabolism indices for pharmacogenetic functional status based on combinatory genotyping of <i>CYP2C9</i> , <i>CYP2C19</i> and <i>CYP2D6</i> genes. <i>Biomarkers in Medicine</i> , 2011, 5, 427-438.	0.6	28

#	ARTICLE	IF	CITATIONS
260	Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1101-1115.	1.5	64
261	<i>Metabolism of Drugs and Xenobiotics.</i> , 2011, , 45-52.		10
262	Role of cytochrome P450 genotype in the steps toward personalized drug therapy. <i>Pharmacogenomics and Personalized Medicine</i> , 2011, 4, 123.	0.4	20
263	Cytochrome P450 2C19 Polymorphism is Associated with Reduced Clopidogrel Response in Cerebrovascular Disease. <i>Yonsei Medical Journal</i> , 2011, 52, 734.	0.9	20
264	Clinical evidence of interaction between clopidogrel and proton pump inhibitors. <i>World Journal of Cardiology</i> , 2011, 3, 153.	0.5	6
265	Faster Onset of Antidepressant Effects of Citalopram Compared With Sertraline in Drug-Naïve First-Episode Major Depressive Disorder in a Chinese Population. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 577-581.	0.7	9
266	Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 721-730.	0.7	22
267	Aminoglycoside-induced suppression of CYP2C19*3 premature stop codon. <i>Pharmacogenetics and Genomics</i> , 2011, 21, 694-700.	0.7	7
268	Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes. <i>Current Drug Metabolism</i> , 2011, 12, 487-497.	0.7	101
269	Pharmacokineticâ€“pharmacodynamic optimization of triazole antifungal therapy. <i>Current Opinion in Infectious Diseases</i> , 2011, 24, S14-S29.	1.3	10
270	Value of preemptive CYP2C19 genotyping in allogeneic stem cell transplant patients considered for pentamidine administration. <i>Clinical Transplantation</i> , 2011, 25, E271-E275.	0.8	5
271	Comparison and evaluation of a novel bioassay and highâ€“performance liquid chromatography for the clinical measurement of serum voriconazole concentrations. <i>Mycoses</i> , 2011, 54, e421-8.	1.8	12
272	Review article: proton pump inhibitors with clopidogrel - evidence for and against a clinically-important interaction. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 33, 758-767.	1.9	12
273	Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. <i>Journal of Cardiology</i> , 2011, 57, 275-282.	0.8	13
274	Current status and prospects of antiplatelet therapy in percutaneous coronary intervention in Japan: Focus on adenosine diphosphate receptor inhibitors. <i>Journal of Cardiology</i> , 2011, 58, 6-17.	0.8	13
275	Clinical Outcomes of High On-Treatment Platelet Reactivity in Koreans Receiving Elective Percutaneous Coronary Intervention (from Results of the CROSS VERIFY Study). <i>American Journal of Cardiology</i> , 2011, 108, 1556-1563.	0.7	39
276	Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. <i>Breast</i> , 2011, 20, 111-118.	0.9	71
277	Pharmacogenomics of the triazole antifungal agent voriconazole. <i>Pharmacogenomics</i> , 2011, 12, 861-872.	0.6	82

#	ARTICLE	IF	CITATIONS
278	The pharmacogenetics of antiplatelet agents: towards personalized therapy?. <i>Nature Reviews Cardiology</i> , 2011, 8, 560-571.	6.1	38
279	Update on the pharmacogenomics of proton pump inhibitors. <i>Pharmacogenomics</i> , 2011, 12, 873-888.	0.6	80
280	Novel strategies for microdose studies using non-radiolabeled compounds. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 532-538.	6.6	47
281	Functional characterization of promoter region polymorphisms of human CYP2C19 gene. <i>Molecular Biology Reports</i> , 2011, 38, 4171-4179.	1.0	7
283	Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 253-260.	0.8	54
284	Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 1223-1229.	0.8	33
285	Implications of Pharmacogenetic Testing for Patients Taking Warfarin or Clopidogrel. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 52-60.	2.0	12
286	Stereoselective pharmacokinetics of stable isotope (+/ ¹³ C)-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity. <i>Chirality</i> , 2011, 23, 904-909.	1.3	21
287	High Doses of Clopidogrel to Overcome Genetic Resistance. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 392-402.	1.1	118
288	Transcriptional regulation and pharmacogenomics. <i>Pharmacogenomics</i> , 2011, 12, 655-673.	0.6	16
289	Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial. <i>Heart</i> , 2011, 97, 641-647.	1.2	42
290	Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies. <i>Journal of Clinical Oncology</i> , 2011, 29, 1271-1279.	0.8	189
291	Effect of CYP2C19*2 and *3 Loss-of-Function Alleles on Platelet Reactivity and Adverse Clinical Events in East Asian Acute Myocardial Infarction Survivors Treated With Clopidogrel and Aspirin. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 585-594.	1.4	112
292	Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours. <i>British Journal of Cancer</i> , 2011, 105, 1173-1175.	2.9	40
293	Genetic variants in CYP1A2, CYP2C9, CYP2C19, CYP3A4 and CYP3A5, VKORC1 and ABCB1 genes in a black South African population: a window into diversity. <i>Pharmacogenomics</i> , 2011, 12, 1663-1670.		60
294	Single nucleotide and copy number polymorphisms of the SULT1A1 gene in a South African Tswana population group. <i>South African Journal of Science</i> , 2011, 107, .	0.3	3
295	Clopidogrel pharmacogenetics: metabolism and drug interactions. <i>Drug Metabolism and Drug Interactions</i> , 2011, 26, 45-51.	0.3	11
296	Impact of proton pump inhibitors on efficacy of clopidogrel: Review of evidence. <i>Indian Journal of Pharmacology</i> , 2011, 43, 183.	0.4	12

#	ARTICLE	IF	CITATIONS
297	A Practitioner's Guide to Prescribing Diazepam for Adults with Intellectual Disabilities. , 2012, , 75-94.		0
298	Development of a Novel, Fully-Automated Genotyping System: Principle and Applications. Sensors, 2012, 12, 16614-16627.	2.1	26
299	Pharmacogenetics and dermatology. , 2012, , 1-14.		0
300	Genetic polymorphisms and novel allelic variants of <i>CYP2C19</i> in the Chinese Han population. Pharmacogenomics, 2012, 13, 1571-1581.	0.6	33
301	Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. Future Oncology, 2012, 8, 451-462.	1.1	48
302	<i>CYP2C19</i> genotype predicts steady state escitalopram concentration in GENDEP. Journal of Psychopharmacology, 2012, 26, 398-407.	2.0	69
303	The Influence of Omeprazole on Platelet Inhibition of Clopidogrel in Various <i>CYP2C19</i> Mutant Alleles. Genetic Testing and Molecular Biomarkers, 2012, 16, 1293-1297.	0.3	15
304	Identification of <i>CYP2C19*4B</i> : pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics Journal, 2012, 12, 297-305.	0.9	40
305	The Dual Role of Pharmacogenetics in HIV Treatment: Mutations and Polymorphisms Regulating Antiretroviral Drug Resistance and Disposition. Pharmacological Reviews, 2012, 64, 803-833.	7.1	85
306	Distribution of <i>CYP2D6</i> and <i>CYP2C19</i> Polymorphisms Associated with Poor Metabolizer Phenotype in Five Amerindian Groups and Western Mestizos from Mexico. Genetic Testing and Molecular Biomarkers, 2012, 16, 1098-1104.	0.3	35
307	Molecular mechanisms of genetic variation and transcriptional regulation of <i>CYP2C19</i> . Frontiers in Genetics, 2012, 3, 206.	1.1	28
308	Relative Copy Number Variations of <i>CYP2C19</i> in South Indian Population. Molecular Biology International, 2012, 2012, 1-4.	1.7	2
309	Dosing Rationale for Fixed-Dose Combinations in Children: Shooting From the Hip?. Clinical Pharmacology and Therapeutics, 2012, 91, 718-725.	2.3	4
310	Evaluating the Relationship Between Carisoprodol Concentrations and Meprobamate Formation and Inter-Subject and Intra-Subject Variability in Urinary Excretion Data of Pain Patients. Journal of Analytical Toxicology, 2012, 36, 221-231.	1.7	7
311	Induction of <i>CYP2C19</i> and <i>CYP3A</i> Activity Following Repeated Administration of Efavirenz in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2012, 91, 475-482.	2.3	36
312	PharmGKB summary. Pharmacogenetics and Genomics, 2012, 22, 159-165.	0.7	141
313	Pharmacogenetic screening for drug therapy: From single gene markers to decision making in the next generation sequencing era. Pathology, 2012, 44, 166-180.	0.3	23
314	Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug Development. Drug Metabolism and Pharmacokinetics, 2012, 27, 9-54.	1.1	200

#	ARTICLE	IF	CITATIONS
315	Ontogenesis of phase I hepatic drug metabolic enzymes in sheep. <i>Reproduction, Fertility and Development</i> , 2012, 24, 425.	0.1	9
316	Comparison of Cytochrome P450 Mediated Metabolism of Three Central Nervous System Acting Drugs. <i>Chemical and Pharmaceutical Bulletin</i> , 2012, 60, 1544-1549.	0.6	8
317	Proton-Pump Inhibitors Could Be Innocent When Used Concomitantly With Clopidogrel. <i>Circulation Journal</i> , 2012, 76, 2542-2543.	0.7	1
318	CytochromeP450 isoenzyme specificity in the metabolism of anti-malarial biguanides: molecular docking and molecular dynamics analyses. <i>Medicinal Chemistry Research</i> , 2012, 21, 4274-4289.	1.1	7
320	<i>Clinical Pharmacogenetics.</i> , 2012, , 195-215.		0
321	Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction. <i>International Journal of Clinical Pharmacy</i> , 2012, 34, 825-827.	1.0	20
322	Association between cytochrome P450 2C19 polymorphism and clinical outcomes in Chinese patients with coronary artery disease. <i>Atherosclerosis</i> , 2012, 220, 168-171.	0.4	18
323	Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents. <i>Heart</i> , 2012, 98, 139-144.	1.2	75
324	Stiripentol: An example of antiepileptic drug development in childhood epilepsies. <i>European Journal of Paediatric Neurology</i> , 2012, 16, S13-S17.	0.7	20
325	Antiplatelet therapy in acute coronary syndromes. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 27-42.	0.9	4
327	Meta-Analysis of Cytochrome P450 2C19 Polymorphism and Risk of Adverse Clinical Outcomes Among Coronary Artery Disease Patients of Different Ethnic Groups Treated With Clopidogrel. <i>American Journal of Cardiology</i> , 2012, 110, 502-508.	0.7	90
328	Invasive Mycoses: Strategies for Effective Management. <i>American Journal of Medicine</i> , 2012, 125, S25-S38.	0.6	68
329	Distribution of <i>CYP2C9*13</i> allele in the Chinese Han and the long-range haplotype containing <i>CYP2C9*13</i> and <i>CYP2C19*2</i> . <i>Biopharmaceutics and Drug Disposition</i> , 2012, 33, 342-345.	1.1	9
330	Clinical Application of Pharmacogenomics. <i>Journal of Pharmacy Practice</i> , 2012, 25, 417-427.	0.5	54
331	How informative is a negative finding in a small pharmacogenetic study?. <i>Pharmacogenomics Journal</i> , 2012, 12, 93-95.	0.9	7
333	A Review of Pharmacogenetics of Adverse Drug Reactions in Elderly People. <i>Drug Safety</i> , 2012, 35, 3-20.	1.4	33
334	llaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial. <i>Current Medical Research and Opinion</i> , 2012, 28, 101-109.	0.9	33
335	Multiplexed Pharmacogenetic Assays for SNP Genotyping: Tools and Techniques for Individualizing Patient Therapy. , 0, ,		1

#	ARTICLE	IF	CITATIONS
336	Pharmacogenomics in Gastroenterology. , 2012, , .		0
338	Effects of 600 mg versus 300 mg Loading Dose of Clopidogrel in Asian Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Long-Term Follow-Up Study. <i>Yonsei Medical Journal</i> , 2012, 53, 906.	0.9	3
339	Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. <i>Bone Marrow Transplantation</i> , 2012, 47, 881-894.	1.3	27
340	Effect of the CYP2C19 genotype on the pharmacokinetics of icotinib in healthy male volunteers. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 1677-1680.	0.8	18
341	Simultaneous determination of triazole antifungal drugs in human plasma by sweeping-micellar electrokinetic chromatography. <i>Analytical and Bioanalytical Chemistry</i> , 2012, 404, 217-228.	1.9	17
342	Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 681-688.	0.8	13
343	The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients. <i>Biochemical Pharmacology</i> , 2012, 83, 903-908.	2.0	31
344	A case of subacute thrombosis associated with clopidogrel resistance after implantation of a zotarolimus-eluting stent. <i>Heart and Vessels</i> , 2012, 27, 106-109.	0.5	6
345	Is (+)-[¹³ C]-pantoprazole better than (±)-[¹³ C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?. <i>Journal of Breath Research</i> , 2013, 7, 016001.	1.5	8
346	Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. <i>Journal of Infection and Chemotherapy</i> , 2013, 19, 381-392.	0.8	149
347	Racial disparity with on-treatment platelet reactivity in patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2013, 166, 266-272.	1.2	31
348	High post-clopidogrel platelet reactivity assessed by a point-of-care assay predicts long-term clinical outcomes in patients with ST-segment elevation myocardial infarction who underwent primary coronary stenting. <i>International Journal of Cardiology</i> , 2013, 167, 1877-1881.	0.8	28
349	An Allele-Specific PCR System for Rapid Detection and Discrimination of the CYP2C19 [∗] 4A, [∗] 4B, and [∗] 17 Alleles. <i>Journal of Molecular Diagnostics</i> , 2013, 15, 783-789.	1.2	17
350	Reported Side Effects and Complications of Long-term Proton Pump Inhibitor Use: Dissecting the Evidence. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 458-464.	2.4	88
351	A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. <i>Forensic Science International</i> , 2013, 226, e26-e31.	1.3	33
352	Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 517-527.	0.7	94
353	Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. <i>Journal of Cardiology</i> , 2013, 62, 158-164.	0.8	28
354	Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. <i>Pharmacogenomics Journal</i> , 2013, 13, 369-377.	0.9	87

#	ARTICLE	IF	CITATIONS
355	Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. , 2013, 138, 103-141.		2,924
357	Challenges in exploring the cytochrome P450 system as a source of variation in canine drug pharmacokinetics. Drug Metabolism Reviews, 2013, 45, 218-230.	1.5	51
358	Do we need pharmacogenetics to personalize antidepressant therapy?. Cellular and Molecular Life Sciences, 2013, 70, 3327-3340.	2.4	6
359	Applications of CYP450 Testing in the Clinical Setting. Molecular Diagnosis and Therapy, 2013, 17, 165-184.	1.6	296
360	Suboptimal response to clopidogrel: A genetic risk factor for recurrent ischaemic stroke. Journal of Clinical Neuroscience, 2013, 20, 767-770.	0.8	9
361	De la bonne utilisation des antifongiques systÃ©miques en rÃ©animation. RÃ©fÃ©rences En RÃ©animation, 2013, , 105-120.	0.0	0
362	High prevalence of CYP2C19*2 allele in Roma samples: study on Roma and Hungarian population samples with review of the literature. Molecular Biology Reports, 2013, 40, 4727-4735.	1.0	22
363	Pharmacogenomics in Pregnancy. , 2013, , 113-127.		1
364	Key Mutations Alter the Cytochrome P450 BM3 Conformational Landscape and Remove Inherent Substrate Bias. Journal of Biological Chemistry, 2013, 288, 25387-25399.	1.6	62
366	Impact of CYP2C19 Genetic Testing on Provider Prescribing Patterns for Antiplatelet Therapy After Acute Coronary Syndromes and Percutaneous Coronary Intervention. Circulation: Cardiovascular Quality and Outcomes, 2013, 6, 694-699.	0.9	14
367	A Case-report of Unpredictable and Massive Voriconazole Intoxication in a Patient with Extensive CYP2C19 and CYP2C9 Polymorphisms. Drug Metabolism and Pharmacokinetics, 2013, 28, 439-441.	1.1	7
368	Pregnancy and pharmacogenomics in the context of drug metabolism and response. Pharmacogenomics, 2013, 14, 1779-1791.	0.6	9
369	Effects of clopidogrel on the platelet activation response in horses. American Journal of Veterinary Research, 2013, 74, 1212-1222.	0.3	22
370	Pharmacogenetic testing: current evidence of clinical utility. Therapeutic Advances in Drug Safety, 2013, 4, 155-169.	1.0	30
371	New antifungal antibiotics. Current Opinion in Infectious Diseases, 2013, 26, 168-174.	1.3	30
372	Steady-State Pharmacokinetics of Oral Voriconazole and Its Primary Metabolite, N-Oxide Voriconazole, Pre- and Post-Autologous Peripheral Stem Cell Transplantation. Antimicrobial Agents and Chemotherapy, 2013, 57, 3420-3423.	1.4	11
373	Effects of Esomeprazole on the Pharmacokinetics of Lapatinib in Breast Cancer Patients. Clinical Pharmacology in Drug Development, 2013, 2, 336-341.	0.8	21
374	Adverse drug interactions as a high-risk factor for lethal post-transplant complications in Chinese population. Clinical Transplantation, 2013, 27, 255-260.	0.8	6

#	ARTICLE	IF	CITATIONS
375	Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells. <i>Leukemia</i> , 2013, 27, 1201-1204.	3.3	7
376	Identifying determinants of variability to tailor aspirin therapy. <i>Expert Review of Cardiovascular Therapy</i> , 2013, 11, 365-379.	0.6	23
377	Genetic Polymorphisms and Drug Interactions Leading to Clopidogrel Resistance: Why the Asian Population Requires Special Attention. <i>International Journal of Neuroscience</i> , 2013, 123, 143-154.	0.8	76
378	Effect of amlodipine on platelet inhibition by clopidogrel in patients with ischaemic heart disease: a randomised, controlled trial. <i>Heart</i> , 2013, 99, 468-473.	1.2	16
379	Human pharmacogenetic analysis in chimeric mice with "humanized livers"™. <i>Pharmacogenetics and Genomics</i> , 2013, 23, 78-83.	0.7	26
380	Measuring Platelet Reactivity after Clopidogrel-Has it Reached the End of the Road?. <i>Cardiovascular Pharmacology: Open Access</i> , 2013, 2, .	0.1	4
381	Economic evaluations of pharmacogenetic approaches in infectious diseases: a review of current approaches and evaluation of critical aspects affecting their quality. <i>Journal of Public Health in Africa</i> , 2013, 4, 18.	0.2	0
382	High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials. <i>Thrombosis and Haemostasis</i> , 2013, 109, 834-845.	1.8	28
383	CYP2C19 Phenotype, Stent Thrombosis, Myocardial Infarction, and Mortality in Patients with Coronary Stent Placement in a Chinese Population. <i>PLoS ONE</i> , 2013, 8, e59344.	1.1	19
384	Prognostic Significance of ESR1 Amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 Polymorphisms in Breast Cancer Patients. <i>PLoS ONE</i> , 2013, 8, e72219.	1.1	20
385	Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department. <i>Vascular Health and Risk Management</i> , 2013, 9, 187.	1.0	10
386	Pharmacogenetics in Cardiovascular Diseases. , 2013, , 133-182.		3
387	Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine. <i>Frontiers in Genetics</i> , 2012, 3, 318.	1.1	59
388	Hemostatic Aspects of Cardiovascular Medicine. , 2013, , 342-394.		0
389	Serum Voriconazole Level Variability in Patients with Hematological Malignancies Receiving Voriconazole Therapy. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2014, 25, 271-276.	0.7	11
390	Genetic polymorphisms of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in Vietnamese-Koreans. <i>Translational and Clinical Pharmacology</i> , 2014, 22, 70.	0.3	8
391	Stiripentol for the treatment of Dravet syndrome. <i>Orphan Drugs: Research and Reviews</i> , 2014, , 29.	0.6	5
392	Pharmacogenetics and polymorphism: future tools for optimizing therapeutic efficacy. <i>Bangladesh Journal of Physiology and Pharmacology</i> , 2014, 26, 34-42.	0.1	0

#	ARTICLE	IF	CITATIONS
393	ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome. European Heart Journal Supplements, 2014, 16, C2-C28.	0.0	2
394	Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures. Expert Opinion on Pharmacotherapy, 2014, 15, 2205-2217.	0.9	4
395	Personalized medicine and the clinical laboratory. Einstein (Sao Paulo, Brazil), 2014, 12, 366-373.	0.3	8
396	Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Internal Medicine Journal, 2014, 44, 1364-1388.	0.5	88
397	Disseminated <i>Scedosporium prolificans</i> infection in an "extensive metaboliser": navigating the minefield of drug interactions and pharmacogenomics. Mycoses, 2014, 57, 572-576.	1.8	23
398	Pharmacogenetics in Jewish populations. Drug Metabolism and Drug Interactions, 2014, 29, 221-233.	0.3	14
399	Pharmacogenomics of Antifungal Agents. , 2014, , 879-900.		8
400	Danggui to Angelica sinensis root: Are potential benefits to European women lost in translation? A review. Journal of Ethnopharmacology, 2014, 152, 1-13.	2.0	77
401	High On-Treatment Platelet Reactivity in Peripheral Endovascular Procedures. CardioVascular and Interventional Radiology, 2014, 37, 559-571.	0.9	6
402	Urinary Diazepam Metabolite Distribution in a Chronic Pain Population. Journal of Analytical Toxicology, 2014, 38, 135-142.	1.7	18
403	CYP2C19 genotype-phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity. Cancer Chemotherapy and Pharmacology, 2014, 73, 651-655.	1.1	16
404	Proton pump inhibitors and clopidogrel: an association to avoid?. Internal and Emergency Medicine, 2014, 9, 11-22.	1.0	13
405	Classics in Chemical Neuroscience: Diazepam (Valium). ACS Chemical Neuroscience, 2014, 5, 253-260.	1.7	190
406	Treatment of gastroesophageal reflux disease: two new oral formulations dexlansoprazole MR and esomezol (esomeprazole strontium). Expert Opinion on Pharmacotherapy, 2014, 15, 1215-1222.	0.9	5
407	Common variants in the CYP2C19 gene are associated with susceptibility to endometriosis. Fertility and Sterility, 2014, 102, 496-502.e5.	0.5	15
408	Antiplatelet drug interactions with proton pump inhibitors. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 175-189.	1.5	35
409	Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent. Pharmacogenomics Journal, 2014, 14, 151-159.	0.9	17
410	Converging Indications of Aldosterone Antagonists (Spironolactone and Eplerenone): A Narrative Review of Safety Profiles. Current Hypertension Reports, 2014, 16, 414.	1.5	30

#	ARTICLE	IF	CITATIONS
411	Factors Impacting Variability of the Urinary Normeperidine-to-Meperidine Metabolic Ratio in Patients with Chronic Pain. <i>Journal of Analytical Toxicology</i> , 2014, 38, 1-7.	1.7	8
412	Benzodiazepines. <i>Journal of Pharmacy Practice</i> , 2014, 27, 5-16.	0.5	176
413	Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians. <i>Pharmacogenomics</i> , 2014, 15, 1147-1157.	0.6	41
414	Role of phenotypic and genetic testing in managing clopidogrel therapy. <i>Blood</i> , 2014, 124, 689-699.	0.6	28
416	Pharmacogenomic testing: the case for <i>CYP2C19</i> proton pump inhibitor gene-drug pairs. <i>Pharmacogenomics</i> , 2014, 15, 1405-1416.	0.6	19
417	Pharmacokinetic Pharmacogenomics. , 2014, , 341-364.		14
419	Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus. <i>Tumor Biology</i> , 2014, 35, 9023-9026.	0.8	3
420	Genetic and non-genetic factors responsible for antiplatelet effects of clopidogrel in Japanese patients undergoing coronary stent implantation: An algorithm to predict on-clopidogrel platelet reactivity. <i>Thrombosis Research</i> , 2014, 134, 877-883.	0.8	8
421	One Size Fits One: Pharmacogenetics in Gastroenterology. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 565-570.	2.4	3
422	Relationship between Smoking and Responsiveness to Clopidogrel in Non-cardiogenic Ischemic Stroke Patients. <i>Internal Medicine</i> , 2014, 53, 2575-2579.	0.3	11
423	Response to Clopidogrel and Its Association with Chronic Kidney Disease in Noncardiogenic Ischemic Stroke Patients. <i>Internal Medicine</i> , 2014, 53, 215-219.	0.3	10
425	Characterization of Patients With Angioscopically-Detected In-Stent Mural Thrombi. <i>Circulation Journal</i> , 2014, 79, 85-90.	0.7	14
426	DNA Dangling-Induced Colloidal Stabilization of Gold Nanoparticles for Colorimetric Single-Nucleotide Polymorphism Genotyping. <i>Chemistry - A European Journal</i> , 2014, 20, 17420-17425.	1.7	29
427	Effects of CYP2C19 Genetic Polymorphisms on Atomoxetine Pharmacokinetics. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 139-142.	0.7	29
428	In vitro inhibitory effects of plumbagin, the promising antimalarial candidate, on human cytochrome P450 enzymes. <i>Asian Pacific Journal of Tropical Medicine</i> , 2015, 8, 914-918.	0.4	12
429	Mechanisms of Action of Antifungal Agents. , 2015, , 183-196.		0
430	Inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label crossover study. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 719-730.	1.9	258
431	Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. <i>Epilepsia</i> , 2015, 56, 1246-1251.	2.6	399

#	ARTICLE	IF	CITATIONS
432	Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1421.	0.9	14
433	P2Y12 inhibitors for acute coronary syndromes: current perspectives. <i>Research Reports in Clinical Cardiology</i> , 2015, , 123.	0.2	0
434	The Effect of MGCD0103 on CYP450 Isoforms Activity of Rats by Cocktail Method. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	5
435	The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation. <i>Molecules</i> , 2015, 20, 2208-2228.	1.7	69
436	Association analysis of CYP2C9*3 and phenytoin-induced severe cutaneous adverse reactions (SCARs) in Thai epilepsy children. <i>Journal of Human Genetics</i> , 2015, 60, 413-417.	1.1	28
437	Human Cytochrome P450 Enzymes. , 2015, , 523-785.		117
438	Dual Antiplatelet Therapy in Acute Ischemic Stroke. <i>Current Atherosclerosis Reports</i> , 2015, 17, 37.	2.0	5
439	Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel. <i>Clinical Pharmacokinetics</i> , 2015, 54, 147-166.	1.6	137
440	Challenges and solutions in medically managed ACS in the Asia-Pacific region: Expert recommendations from the Asia-Pacific ACS Medical Management Working Group. <i>International Journal of Cardiology</i> , 2015, 183, 63-75.	0.8	15
441	Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 771-779.	0.9	21
442	Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1161-5.	1.3	26
443	Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch Regimens in Immunocompromised Japanese Pediatric Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 1004-1013.	1.4	22
444	Enhanced Metabolizing Activity of Human ES Cell-Derived Hepatocytes Using a 3D Culture System with Repeated Exposures to Xenobiotics. <i>Toxicological Sciences</i> , 2015, 147, 190-206.	1.4	32
445	Creatine kinase inhibits ADP-induced platelet aggregation. <i>Scientific Reports</i> , 2014, 4, 6551.	1.6	11
446	CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 1269-1279.	1.5	42
447	CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419. <i>International Journal of Cardiology</i> , 2015, 186, 282-285.	0.8	6
448	Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 617-624.	0.8	23
449	Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole. <i>Current Fungal Infection Reports</i> , 2015, 9, 74-87.	0.9	38

#	ARTICLE	IF	CITATIONS
450	Independent and combined effects of environmental factors and CYP2C19 polymorphisms on the risk of esophageal squamous cell carcinoma in Fujian Province of China. <i>BMC Medical Genetics</i> , 2015, 16, 15.	2.1	5
451	Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 699-705.	0.8	4
452	Influence of Inflammation on Voriconazole Metabolism. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 2942-2943.	1.4	38
453	Achieving best outcomes for patients with cardiovascular disease in China by enhancing the quality of medical care and establishing a learning health-care system. <i>Lancet, The</i> , 2015, 386, 1493-1505.	6.3	74
454	Long-Term Loss of Response in Proton Pump Inhibitor-Responsive Esophageal Eosinophilia Is Uncommon and Influenced by CYP2C19 Genotype and Rhinoconjunctivitis. <i>American Journal of Gastroenterology</i> , 2015, 110, 1567-1575.	0.2	102
455	MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells. <i>Biochemical Pharmacology</i> , 2015, 98, 215-223.	2.0	51
456	Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents. <i>Drugs</i> , 2015, 75, 1613-1625.	4.9	7
457	CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2015, 354, 426-430.	1.3	30
458	Clinical usefulness of therapeutic drug monitoring of voriconazole in a university hospital. <i>Enfermedades Infecciosas Y MicrobiologÍa ClÍnica</i> , 2015, 33, 298-302.	0.3	19
459	Clinical applications of CYP genotyping in psychiatry. <i>Journal of Neural Transmission</i> , 2015, 122, 5-28.	1.4	122
460	Acute Coronary Syndrome. <i>Journal of Intensive Care Medicine</i> , 2015, 30, 186-200.	1.3	94
461	Is personalized medicine a dream or a reality?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015, 52, 1-11.	2.7	24
462	Pharmaco-genomics of antiretroviral drugs. , 0, , 297-312.		0
463	Simultaneous Two-Vessel Subacute Stent Thrombosis Caused by Clopidogrel Resistance from CYP2C19 Polymorphism. <i>Case Reports in Medicine</i> , 2016, 2016, 1-4.	0.3	2
464	Multicenter Study of Antibiotic Resistance Profile of <i>H. pylori</i> and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China. <i>Gastroenterology Research and Practice</i> , 2016, 2016, 1-6.	0.7	19
465	Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature. <i>PLoS ONE</i> , 2016, 11, e0146262.	1.1	94
466	Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1142-1152.	1.1	18
467	Effects of various antiplatelet drugs on ex vivo platelet activation induced by equine herpesvirus type 1. <i>American Journal of Veterinary Research</i> , 2016, 77, 1366-1373.	0.3	3

#	ARTICLE	IF	CITATIONS
468	Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. <i>BMC Medicine</i> , 2016, 14, 179.	2.3	300
469	Genetic Polymorphisms and <i>In Vitro</i> Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants. <i>Biological and Pharmaceutical Bulletin</i> , 2016, 39, 1748-1759.	0.6	32
470	Rapid Naked-Eye Discrimination of Cytochrome P450 Genetic Polymorphism through Non-Crosslinking Aggregation of DNA-Functionalized Gold Nanoparticles. <i>ChemistryOpen</i> , 2016, 5, 507-507.	0.9	5
471	Pharmacogenetic studies: a tool to improve antidepressant therapy. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 197-204.	0.3	10
472	The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole- ¹³ C breath test in GERD patients: clinical relevance for personalized medicine. <i>Journal of Breath Research</i> , 2016, 10, 046017.	1.5	12
473	Rapid Naked-Eye Discrimination of Cytochrome P450 Genetic Polymorphism through Non-Crosslinking Aggregation of DNA-Functionalized Gold Nanoparticles. <i>ChemistryOpen</i> , 2016, 5, 508-512.	0.9	22
474	Pharmacodynamics of Antimalarial Agents. <i>Methods in Pharmacology and Toxicology</i> , 2016, , 415-439.	0.1	0
475	The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy. <i>American Journal of Gastroenterology</i> , 2016, 111, 949-956.	0.2	88
476	Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy. <i>Molecular Biology Reports</i> , 2016, 43, 473-484.	1.0	14
477	Rapid and ultra-rapid metabolizers with CYP2C19 *17 polymorphism do not respond to standard therapy with proton pump inhibitors. <i>Meta Gene</i> , 2016, 9, 159-164.	0.3	25
478	Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle-cell disease patients and healthy controls in Nigeria. <i>Pharmacology Research and Perspectives</i> , 2016, 4, e00252.	1.1	1
479	Effect of antituberculosis treatment on CYP2C19 enzyme activity in genetically polymorphic South Indian Tamilian population. <i>Fundamental and Clinical Pharmacology</i> , 2016, 30, 607-615.	1.0	0
480	Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1185-1193.	0.8	46
481	Pramipexole in the treatment of REM sleep behaviour disorder: A critical review. <i>Psychiatry Research</i> , 2016, 243, 365-372.	1.7	14
482	Payer view of personalized medicine. <i>American Journal of Health-System Pharmacy</i> , 2016, 73, 2007-2012.	0.5	16
483	Landscape of warfarin and clopidogrel pharmacogenetic variants in Qatari population from whole exome datasets. <i>Pharmacogenomics</i> , 2016, 17, 1891-1901.	0.6	14
484	Association of CYP2C19 Polymorphisms with the Clinical Efficacy of Clopidogrel Therapy in Patients Undergoing Carotid Artery Stenting in Asia. <i>Scientific Reports</i> , 2016, 6, 25478.	1.6	31
485	Estimation and Correction of the Blood Volume Variations of Dried Blood Spots Using a Postcolumn Infused-Internal Standard Strategy with LC-Electrospray Ionization-MS. <i>Analytical Chemistry</i> , 2016, 88, 6457-6464.	3.2	19

#	ARTICLE	IF	CITATIONS
486	G-DOC Plus – an integrative bioinformatics platform for precision medicine. BMC Bioinformatics, 2016, 17, 193.	1.2	39
487	Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections. Expert Review of Anti-Infective Therapy, 2016, 14, 731-746.	2.0	20
488	Dydrogesterone metabolism in human liver by aldo-keto reductases and cytochrome P450 enzymes. Xenobiotica, 2016, 46, 868-874.	0.5	2
489	Can Humanized Mice Predict Drug –Behavior–in Humans?. Annual Review of Pharmacology and Toxicology, 2016, 56, 323-338.	4.2	32
490	High CYP2C19 phenotypic variability in gastrointestinal cancer patients. Cancer Chemotherapy and Pharmacology, 2016, 77, 195-204.	1.1	6
491	CYP2C19 drug-drug and drug-gene interactions in ED patients. American Journal of Emergency Medicine, 2016, 34, 245-249.	0.7	7
492	Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults. European Journal of Pharmaceutical Sciences, 2016, 82, 64-78.	1.9	26
493	Genotype-phenotype analysis of CYP2C19 in the Tibetan population and its potential clinical implications in drug therapy. Molecular Medicine Reports, 2016, 13, 2117-2123.	1.1	12
494	Technical Validation of a Next-Generation Sequencing Assay for Detecting Actionable Mutations in Patients with Gastrointestinal Cancer. Journal of Molecular Diagnostics, 2016, 18, 416-424.	1.2	11
495	Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations. Antimicrobial Agents and Chemotherapy, 2016, 60, 2727-2731.	1.4	51
496	Antifungal Agents. Infectious Disease Clinics of North America, 2016, 30, 51-83.	1.9	264
497	BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs. AAPS Journal, 2016, 18, 251-260.	2.2	60
498	Genetic polymorphisms of the drug-metabolizing enzyme CYP2C19 in the Uyghur population in northwest China. Xenobiotica, 2016, 46, 634-640.	0.5	4
499	CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. Journal of Neurosurgery, 2016, 124, 1746-1751.	0.9	24
500	Platelet function testing: does a randomized controlled trial settle the debate?. Journal of NeuroInterventional Surgery, 2016, 8, 768-769.	2.0	3
501	Effects of CYP2C19 variants on methadone metabolism in vitro. Drug Testing and Analysis, 2017, 9, 634-639.	1.6	22
502	Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy. Clinical Pharmacology and Therapeutics, 2017, 102, 493-501.	2.3	19
503	Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population. Genetic Testing and Molecular Biomarkers, 2017, 21, 298-304.	0.3	8

#	ARTICLE	IF	CITATIONS
504	Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 886-898.	1.0	16
505	Cytochrome P450-mediated metabolism of triclosan attenuates its cytotoxicity in hepatic cells. <i>Archives of Toxicology</i> , 2017, 91, 2405-2423.	1.9	37
506	Correlation between cytochrome P450 2C19 genetic polymorphism and treatment response to escitalopram in panic disorder. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 279-284.	0.7	12
507	The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, Tj ETQq1 1 0.784B34 rgBT 49verlock	1.0	19
508	Effects of CYP2C19 Variants on Fluoxetine Metabolism in vitro. <i>Pharmacology</i> , 2017, 100, 91-97.	0.9	6
509	Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention " A multicenter study. <i>International Journal of Cardiology</i> , 2017, 240, 360-366.	0.8	13
510	Effects of cytochrome P450 3A4 and non-genetic factors on initial voriconazole serum trough concentrations in hematological patients with different cytochrome P450 2C19 genotypes. <i>Xenobiotica</i> , 2017, 47, 1121-1129.	0.5	17
511	A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 290-297.	1.2	20
512	Epistatic interactions among CYP2C19*2, CYP3A4 and GSTP1 on the cyclophosphamide therapy in lupus nephritis patients. <i>Pharmacogenomics</i> , 2017, 18, 1401-1411.	0.6	11
513	Pharmacogenetics: a general review on progress to date. <i>British Medical Bulletin</i> , 2017, 124, 1-15.	2.7	48
514	Relationship Between the CYP2C19 Phenotype Using the Voriconazole-to-Voriconazole N-Oxide Plasma Concentration Ratio and Demographic and Clinical Characteristics of Japanese Patients With Different CYP2C19 Genotypes. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 514-521.	1.0	27
515	Case of mycotic cyst caused by Scedosporium apiospermum developed liver dysfunction following administration of voriconazole. <i>Journal of Dermatology</i> , 2017, 44, e296-e297.	0.6	5
516	Polymorphisms of CYP2C8 , CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population. <i>Gene</i> , 2017, 627, 451-459.	1.0	28
517	Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database. <i>Drug Safety</i> , 2017, 40, 895-909.	1.4	13
518	CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 235-246.	1.0	29
519	The dawn of neurosurgery in pre-conquest Mesoamerican territories. <i>Child's Nervous System</i> , 2017, 33, 1621-1629.	0.6	3
520	Pharmacogenetics of Drug Metabolism. , 2017, , 327-345.		10
521	Drug Classification and Drug Disposition Prediction. , 2017, , 102-129.		0

#	ARTICLE	IF	CITATIONS
522	Safety and Efficacy of Prasugrel with Endovascular Treatment for Unruptured Cerebral Aneurysm. <i>Journal of Neuroendovascular Therapy</i> , 2017, 11, 553-557.	0.1	6
523	Admission Glucose and In-hospital Mortality after Acute Myocardial Infarction in Patients with or without Diabetes. <i>Chinese Medical Journal</i> , 2017, 130, 767-775.	0.9	18
524	Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1335-1345.	1.1	10
525	Clinical Pharmacokinetics and the Impact of Genetic Polymorphism on a CYP2C19 Substrate, BMS-823778, in Healthy Subjects. <i>Drug Metabolism and Disposition</i> , 2018, 46, 316-325.	1.7	10
526	Development of a Polymerase Chain Reaction/Ligase Detection Reaction Assay for Detection of CYP2C19 Polymorphisms. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 62-73.	0.3	2
527	Voriconazole concentration is inversely correlated with corticosteroid usage in immunocompromised patients. <i>Transplant Infectious Disease</i> , 2018, 20, e12886.	0.7	12
528	Blood biomarkers and treatment response in major depression. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 513-529.	1.5	58
529	Metabolic profiling of corylin in vivo and in vitro. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 155, 157-168.	1.4	16
530	Point-of-care companion diagnostic tests for personalizing psychiatric medications: fulfilling an unmet clinical need. <i>Journal of Breath Research</i> , 2018, 12, 017101.	1.5	6
531	Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11 β -hydroxysteroid dehydrogenase type 1 inhibitor BMS-823778. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 130-141.	1.1	11
532	Association Between CYP2C19*17 Alleles and pH Probe Testing Outcomes in Children With Symptomatic Gastroesophageal Reflux. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 89-96.	1.0	22
533	Functional characterization of CYP2C19 variants in neбиволol 4-hydroxylation in vitro. <i>Drug Testing and Analysis</i> , 2018, 10, 807-813.	1.6	7
534	Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 285-296.	0.8	6
535	Association between CYP2C19 extensive metabolizer phenotype and childhood anti-reflux surgery following failed proton pump inhibitor medication treatment. <i>European Journal of Pediatrics</i> , 2018, 177, 69-77.	1.3	20
536	The effects of cytochrome P450 2C19 polymorphism on the metabolism of voriconazole in vitro. <i>Infection and Drug Resistance</i> , 2018, Volume 11, 2129-2135.	1.1	13
537	Pharmacogenomics of Medications Commonly Used in the Intensive Care Unit. <i>Frontiers in Pharmacology</i> , 2018, 9, 1436.	1.6	12
538	Clinical application and importance of one-step human CYP2C19 genotype detection. <i>Journal of International Medical Research</i> , 2018, 46, 4965-4973.	0.4	2
539	Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. <i>Journal of Personalized Medicine</i> , 2018, 8, 8.	1.1	65

#	ARTICLE	IF	CITATIONS
540	Pharmacogenomics in Papua New Guineans. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 153-164.	0.7	6
541	In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> . 2018, 158, 351-360.	1.4	10
542	Clopidogrel Pharmacokinetics in Malaysian Population Groups: The Impact of Inter-Ethnic Variability. <i>Pharmaceuticals</i> , 2018, 11, 74.	1.7	4
543	Effects of CYP2C19 and CYP3A5 genetic polymorphisms on the pharmacokinetics of cilostazol and its active metabolites. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1417-1426.	0.8	16
544	Genomics and Drug-Metabolizing Enzymes and Its Application in Drug Delivery: Evaluating the Influence of the Microbiome. , 2018, , 177-200.		0
545	Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks. , 2018, , 269-291.		3
546	Effects of genetic polymorphisms of CYP2C19 on the pharmacokinetics of zolpidem. <i>Archives of Pharmacal Research</i> , 2018, 41, 861-866.	2.7	9
547	Cytochrome P450 genotypeâ€­guided drug therapies: An update on current states. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 991-1001.	0.9	19
548	Metabolism of Drugs and Xenobiotics. , 2018, , 319-326.		0
549	Clinical Chemistry Applications of Capillary Electromigration Methods. , 2018, , 423-452.		3
550	Non-Crosslinking Aggregation of DNA-Functionalized Gold Nanoparticles for Gene Diagnosis and Directed Assembly. <i>ACS Symposium Series</i> , 2019, , 119-138.	0.5	4
551	Genetics and Extracellular Vesicles of Pediatrics Sleep Disordered Breathing and Epilepsy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5483.	1.8	8
552	Relation of Sex and Race to Outcomes in Patients Undergoing Percutaneous Intervention With Drug-Eluting Stents. <i>American Journal of Cardiology</i> , 2019, 123, 913-918.	0.7	14
553	Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study. <i>PLoS ONE</i> , 2019, 14, e0221750.	1.1	8
554	Assessing pharmacokinetic differences in Caucasian and East Asian (Japanese, Chinese and Korean) populations driven by CYP2C19 polymorphism using physiologically-based pharmacokinetic modelling. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 139, 105061.	1.9	23
555	Physiologically Based Pharmacokinetic Modeling Approach to Predict Drugâ€­Drug Interactions With Ethionamide Involving Impact of Genetic Polymorphism on FMO3. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 880-889.	1.0	7
556	Clinical consequences related to a defective elimination of clobazam caused by homozygous mutated CYP2C19 allele. <i>Clinical Toxicology</i> , 2019, 57, 743-747.	0.8	4
557	Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods. <i>Contemporary Clinical Trials</i> , 2019, 78, 27-33.	0.8	9

#	ARTICLE	IF	CITATIONS
558	Variability in human drug metabolizing cytochrome P450 CYP2C9, CYP2C19 and CYP3A5 activities caused by genetic variations in cytochrome P450 oxidoreductase. <i>Biochemical and Biophysical Research Communications</i> , 2019, 515, 133-138.	1.0	19
559	Early Secondary Prevention in Transient Ischemic Attack (TIA) and Minor Stroke. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 34.	2.0	8
560	Revitalizing antifolates through understanding mechanisms that govern susceptibility and resistance. <i>MedChemComm</i> , 2019, 10, 880-895.	3.5	16
561	Association between CYP2C19*2/*3 Polymorphisms and Coronary Heart Disease. <i>Current Medical Science</i> , 2019, 39, 44-51.	0.7	8
562	Safety and Efficacy of Low-Dose Prasugrel as Part of Triple Therapy With Aspirin and Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Interventionâ€• From the TWMMU-AF PCI Registry â€•. <i>Circulation Journal</i> , 2019, 83, 1000-1005.	0.7	10
563	CYP2C19 and 3A4 Dominate Metabolic Clearance and Bioactivation of Terbinafine Based on Computational and Experimental Approaches. <i>Chemical Research in Toxicology</i> , 2019, 32, 1151-1164.	1.7	12
564	Pharmacokinetics of serotonergic drugs: focus on OCD. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 261-273.	1.5	8
565	Association of cytochrome P450 2C19 *2 and *3 variants with type 2 diabetes mellitus in Chinese population. <i>Journal of Xiangya Medicine</i> , 2019, 4, 34-34.	0.2	1
566	An unusual case of proton pump inhibitor induced hyperchromograninemia. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2019, 9, 511-514.	0.4	0
567	CYP2C19 genetic polymorphism in the Vietnamese population. <i>Annals of Human Biology</i> , 2019, 46, 491-497.	0.4	10
568	Antiplatelet Therapy in Cardiovascular Medicine. , 2019, , 396-414.		0
569	The challenges of treating aspergillus abdominal aneurysm after hematopoietic cell transplant: Rapid voriconazole metabolizer. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 703-705.	0.5	2
570	CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis. <i>Platelets</i> , 2019, 30, 229-240.	1.1	42
571	Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning. <i>International Journal of Hematology</i> , 2020, 111, 84-92.	0.7	9
572	Comparative Effect of Proton-Pump Inhibitors on the Success of Triple and Quadruple Therapy for <i>Helicobacter pylori</i; Infection. <i>Digestive Diseases</i> , 2020, 38, 408-414.	0.8	3
573	Pharmacogenomics for Primary Care: An Overview. <i>Genes</i> , 2020, 11, 1337.	1.0	30
574	Reduction in Tamoxifen Metabolites Endoxifen and N-desmethyltamoxifen With Chronic Administration of Low Dose Cannabidiol: A CYP3A4 and CYP2D6 Drug Interaction. <i>Journal of Pharmacy Practice</i> , 2022, 35, 322-326.	0.5	13
575	Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes. <i>Archives of Pharmacal Research</i> , 2020, 43, 1356-1363.	2.7	14

#	ARTICLE	IF	CITATIONS
576	Impact of gender, albumin, and CYP2C19 polymorphisms on valproic acid in Chinese patients: a population pharmacokinetic model. Journal of International Medical Research, 2020, 48, 030006052095228.	0.4	10
577	The Natural History of Epilepsy. , 2020, , 1-13.		0
578	Challenges in Identifying Medication-Resistant Epilepsy. , 2020, , 14-19.		0
579	International League Against Epilepsy's Definition of Medication-Resistant Epilepsy. , 2020, , 20-26.		0
580	The Economic Impact of Medication-Resistant Epilepsy. , 2020, , 27-33.		0
581	Social Consequences of Medication-Resistant Epilepsy. , 2020, , 34-38.		0
582	Mortality and Morbidity of Medication-Resistant Epilepsy. , 2020, , 39-50.		0
583	Models for Medication-Resistant Epilepsy. , 2020, , 51-61.		0
584	Neurobiology of Medication-Resistant Epilepsy. , 2020, , 62-68.		0
585	Genetic Causes of Medication-Resistant Epilepsy. , 2020, , 69-78.		0
586	Malformations of Cortical Development as Causes of Medication-Resistant Epilepsy. , 2020, , 79-86.		0
587	Hippocampal Sclerosis as a Cause of Medication-Resistant Epilepsy. , 2020, , 87-99.		0
588	Autoimmune Causes of Medication-Resistant Epilepsy. , 2020, , 100-117.		0
589	Medication-Resistant Epilepsy Syndromes in Children. , 2020, , 118-157.		0
590	Medication-Resistant Epilepsy in Adults. , 2020, , 158-170.		1
591	Approach to the Treatment of Medication-Resistant Epilepsy. , 2020, , 171-178.		0
592	Pharmacotherapy for Medication-Resistant Epilepsy. , 2020, , 179-186.		2
593	Reproductive Health for Women with Medication-Resistant Epilepsy. , 2020, , 187-197.		0

#	ARTICLE	IF	CITATIONS
594	Resective Surgery for Medication-Resistant Epilepsy. , 2020, , 198-209.		0
595	Ablative Surgery for Medication-Resistant Epilepsy. , 2020, , 210-218.		0
596	Stimulation Treatment for Medication-Resistant Epilepsy. , 2020, , 219-240.		0
597	Diet Therapy for Medication-Resistant Epilepsy. , 2020, , 241-247.		0
598	Botanical Treatments for Medication-Resistant Epilepsy. , 2020, , 248-255.		0
599	Psychiatric Comorbidities in Medication-Resistant Epilepsy. , 2020, , 256-268.		0
600	A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. <i>Pharmaceutics</i> , 2020, 12, 1191.	2.0	17
601	Pharmacogenomics and Psychopharmacology. , 2020, , 151-202.		2
602	Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-Lasting Inhibition of CYP2C19. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 1254-1264.	2.3	13
603	Impacts of CYP2C19 Polymorphism and Clopidogrel Dosing on in-Stent Restenosis: A Retrospective Cohort Study in Chinese Patients. <i>Drug Design, Development and Therapy</i> , 2020, Volume 14, 669-676.	2.0	4
604	The increasing challenge of the possible impact of ethnicity on psychopharmacology. <i>CNS Spectrums</i> , 2021, 26, 222-231.	0.7	5
605	Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 201-211.	1.0	19
606	The atypical neuroleptics iloperidone and lurasidone inhibit human cytochrome P450 enzymes in vitro. Evaluation of potential metabolic interactions. <i>Pharmacological Reports</i> , 2020, 72, 1685-1694.	1.5	11
607	Polymorphisms. , 2021, , 21-33.e2.		5
608	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1417-1423.	2.3	157
609	Neuro-Interventional Use of Oral Antiplatelets: A Survey of Neuro-Endovascular Centers in the United States and Review of the Literature. <i>Journal of Pharmacy Practice</i> , 2021, 34, 207-215.	0.5	13
610	Pharmacogenetics of Obsessive-Compulsive Disorder: An Evidence-Update. <i>Current Topics in Behavioral Neurosciences</i> , 2021, 49, 385-398.	0.8	5
611	A Machine Learning-Based Biological Drug-Target Interaction Prediction Method for a Tripartite Heterogeneous Network. <i>ACS Omega</i> , 2021, 6, 3037-3045.	1.6	12

#	ARTICLE	IF	CITATIONS
612	The influence of acute coronary syndrome on the levels of clopidogrel active metabolite and platelet inhibition in patients with and without CYP2C19 and ABCB1 gene polymorphisms. <i>Postepy W Kardiologii Interwencyjnej</i> , 2021, 17, 179-186.	0.1	1
613	Enriching Medication Review with a Pharmacogenetic Profile – A Case of Tamoxifen Adverse Drug Reactions. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 279-286.	0.4	4
614	Comparative study of prophylaxis with high and low doses of voriconazole in children with malignancy. <i>Current Medical Mycology</i> , 2020, 6, 27-34.	0.8	1
615	Cilostazol Versus Aspirin for Secondary Stroke Prevention: Systematic Review and Meta-Analysis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105581.	0.7	7
616	The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD). <i>Molecules</i> , 2021, 26, 1987.	1.7	30
617	PHARMACOGENETIC BASES OF INDIVIDUAL SENSITIVITY AND PERSONALIZED ADMINISTRATION OF ANTIPLATELET THERAPY IN DIFFERENT ETHNIC GROUPS. <i>Farmatsiya I Farmakologiya</i> , 2021, 8, 392-404.	0.2	2
618	Han Chinese specific cytochrome P450 polymorphisms and their impact on the metabolism of anti-hypertensive drugs with adrenoceptor blocking properties. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 707-716.	1.5	4
619	Cytochrome P450 2C19 gene polymorphisms (CYP2C19*2 and CYP2C19*3) in chronic myeloid leukemia patients: <i>in vitro</i> and <i>in silico</i> studies. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 9389-9402.	2.0	6
620	Voriconazole Use in Children: Therapeutic Drug Monitoring and Control of Inflammation as Key Points for Optimal Treatment. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 456.	1.5	7
621	Classification of drugs for evaluating drug interaction in drug development and clinical management. <i>Drug Metabolism and Pharmacokinetics</i> , 2021, 41, 100414.	1.1	12
622	PON1 Q192R is associated with high platelet reactivity with clopidogrel in patients undergoing elective neurointervention: A prospective single-center cohort study. <i>PLoS ONE</i> , 2021, 16, e0254067.	1.1	1
623	Azoles. , 2011, , 61-93.		1
624	Applications of Microarrays and Biochips in Pharmacogenomics. <i>Methods in Molecular Biology</i> , 2008, 448, 21-30.	0.4	16
626	Genetic Polymorphisms of Cytochrome P450 and Antidepressants. , 2016, , 533-543.		2
627	Pharmacokinetic – Pharmacodynamic Basis of Optimal Antibiotic Therapy. , 2012, , 1433-1452.e10.		2
629	Coadministration of Esomeprazole With Fosamprenavir Has No Impact on Steady-State Plasma Amprenavir Pharmacokinetics. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006, 42, 61-67.	0.9	28
630	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use. , 0, , 343-371.		3
631	GERD 2003 – A Consensus on the Way Ahead. <i>Digestion</i> , 2003, 67, 111-117.	1.2	41

#	ARTICLE	IF	CITATIONS
633	Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2017, 22, 31-37.	0.5	12
634	The down-regulation of the CYP2C19 gene is associated with aggressive tumor potential and the poorer recurrence-free survival of hepatocellular carcinoma. <i>Oncotarget</i> , 2018, 9, 22058-22068.	0.8	15
635	Creatine kinase, energy reserve, and hypertension: from bench to bedside. <i>Annals of Translational Medicine</i> , 2018, 6, 292-292.	0.7	24
636	The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. <i>OncoTargets and Therapy</i> , 2014, 7, 969.	1.0	49
637	CYP2C19 polymorphisms in the Thai population and the clinical response to clopidogrel in patients with atherothrombotic-risk factors. <i>Pharmacogenomics and Personalized Medicine</i> , 2013, 6, 85.	0.4	28
638	Evaluation of changes in cytochrome P450 2C19 activity in type 2 diabetic rats before and after treatment, by using isolated perfused liver model. <i>Iranian Journal of Basic Medical Sciences</i> , 2020, 23, 629-635.	1.0	9
639	How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?. <i>Frontiers in Genetics</i> , 2020, 11, 491895.	1.1	28
640	Relationship between cytochrome P450 2C19*17 genotype distribution platelet aggregation and bleeding risk in patients with blood stasis syndrome of coronary artery disease treated with clopidogrel. <i>Zhong Xi Yi Jie He Xue Bao</i> , 2012, 10, 647-654.	0.7	9
642	Detection of Clopidogrel Hyporesponsiveness Using a Point-of-Care Assay and the Impact of Additional Cilostazol Administration after Coronary Stent Implantation in Diabetic Patients. <i>Korean Journal of Internal Medicine</i> , 2011, 26, 145.	0.7	11
643	A Question About the Potential Cardiac Toxicity of Escitalopram. <i>Journal of Psychosocial Nursing and Mental Health Services</i> , 2012, 50, 17-20.	0.3	7
644	Changes in Antidepressant Metabolism and Dosing Across Pregnancy and Early Postpartum. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 652-658.	1.1	125
645	Relationship between clopidogrel-related polymorphisms and variable platelet reactivity at 1 year: A cohort study from Han Chinese. <i>Journal of Research in Medical Sciences</i> , 2016, 21, 111.	0.4	7
646	Aspirin and clopidogrel resistance in Indian patients with ischemic stroke and its associations with gene polymorphisms: A pilot study. <i>Annals of Indian Academy of Neurology</i> , 2019, 22, 147.	0.2	15
647	Alternative Toxicity of Phthalates. , 2013, 03, .		1
648	Gender Differences in the Pharmacokinetics of Oral Drugs. <i>Pharmacology & Pharmacy</i> , 2011, 02, 31-41.	0.2	14
649	Short-duration triple antithrombotic therapy for atrial fibrillation patients who require coronary stenting: results of the SAFE-A study. <i>EuroIntervention</i> , 2020, 16, e164-e172.	1.4	10
650	Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention. <i>Pharmacy Practice</i> , 2014, 12, 0-0.	0.8	21
651	Investigation of Degradation Mechanism of Rabeprazole with Solid State Pharmaceutical Excipients. <i>Journal of Pharmaceutical Investigation</i> , 2010, 40, 367-372.	2.7	2

#	ARTICLE	IF	CITATIONS
652	Nose to Brain Delivery of Phenytoin Sodium Loaded Nano Lipid Carriers: Formulation, Drug Release, Permeation and In Vivo Pharmacokinetic Studies. <i>Pharmaceutics</i> , 2021, 13, 1640.	2.0	14
654	Drug-Metabolizing Enzymes and P-Glycoprotein. , 2004, , 43-67.		0
655	Interethnic Differences in Drug Response. <i>Drugs and the Pharmaceutical Sciences</i> , 2005, , 221-246.	0.1	2
657	Pharmacogenetics in Infectious Diseases. , 2006, , 155-187.		0
660	Genetics and Psychiatry. , 2008, , 853-883.		0
661	Drug-Metabolizing Enzymes. , 2009, , 85-117.		0
662	Variability of the antiplatelet effect of clopidogrel in Japanese. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2009, 20, 589-593.	0.1	0
665	Clopidogrel and Salicylates. , 2011, , 139-153.		0
667	5. Drug Interaction between Clopidogrel and Proton Pump Inhibitors. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2011, 42, 383-388.	0.1	0
668	Personalizing HIV Therapy, Mission Impossible?. <i>Journal of Antivirals & Antiretrovirals</i> , 2012, 05, .	0.1	0
669	Pharmacogenetics: The Scientific Basis. , 0, , .		0
670	The effectiveness of clopidogrel in the prevention of thrombotic complications in patients with acute coronary syndrome and genetic factors. <i>Kazan Medical Journal</i> , 2012, 93, 294-297.	0.1	1
672	Investigation of Voriconazole Pharmacokinetic Parameters to Schedule Safety Dosage. <i>Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)</i> , 2013, 39, 571-580.	0.0	1
673	Importance of pharmacogenetics for therapeutic use of clopidogrel. <i>Racionalna Terapija</i> , 2013, 5, 75-83.	0.1	0
674	Pharmacogenomic Testing of Anti-Platelets Drugs and its Cost- Effectiveness. , 2013, 03, .		2
675	Hemostasis and Thrombosis. , 2013, , 602-611.		1
677	The Pharmacogenomics of Cytochrome P450s: From Molecular to Clinical Application. , 2014, , 345-370.		1
678	Genetic polymorphisms associated with antiepileptic metabolism. <i>Frontiers in Bioscience - Elite</i> , 2014, 6, 377-386.	0.9	14

#	ARTICLE	IF	CITATIONS
679	Pharmacogenomicsâ€™Pharmacoepigenomics of Breast Cancer Therapy: Clinical Implications. , 2014, , 499-518.		0
680	In Silico-based Study of Cytochrome P450 and Multidrug Resistance Protein 1 from Docking Perspective to Understand Kidney Failure. MGM Journal of Medical Sciences, 2015, 2, 173-178.	0.1	1
681	CYP2C19: The Support Crew II. , 2015, , 53-55.		0
682	Clopidogrel (I): Bagel Brunch. , 2015, , 681-684.		0
683	Introduction to Human Cytochrome P450 Superfamily. , 2016, , 1-100.		0
685	Bioequivalence Study of Two Oral-Capsule Formulations of Omeprazole 20 mg in Combination with Sodium Bicarbonate in Healthy Mexican Adult Volunteers. Journal of Bioequivalence Studies, 0, , .	0.0	0
686	Pharmacogenomics Genome Wide Association Clinical Studies. , 2017, , 14-30.		0
687	Assessing the Toxic Load and Detoxification Strategies. , 2017, , 555-576.		0
688	Assessing the Toxic Load and Detoxification Strategies. , 2017, , 555-576.		0
689	Design and Data Analysis in Drug Interaction Studies. , 2018, , 285-315.		0
690	Effect of proton pump inhibitors on cytochrome P450 2c19 activity in patients with gastroesophageal reflux disease.. Klinicheskaia Meditsina, 2018, 96, 164-167.	0.2	0
691	Preliminary Experience of Preoperative Modification of Platelet Aggregation. Journal of Neuroendovascular Therapy, 2019, 13, 250-256.	0.1	2
692	Choice of protonic pump inhibitor with regard to multimorbidity: a focus on rabeprazol. Meditsinskiy Sovet, 2019, , 34-42.	0.1	2
696	Pharmacogenomics in pregnancy. , 2022, , 111-124.		0
697	Pharmacogenomics and pharmacoepigenomics: Impact on therapeutic strategies. , 2020, , 413-446.		0
698	Pharmacogenomics Genome Wide Association Clinical Studies. Advances in Medical Technologies and Clinical Practice Book Series, 0, , 218-233.	0.3	0
699	ResponseprÃdiktion durch Genotypisierung. , 2005, , 569-588.		0
700	Laboratory Investigation of Vitamin B 12 Deficiency. Laboratory Medicine, 2006, 37, 166-174.	0.8	2

#	ARTICLE	IF	CITATIONS
703	JNMA points to the need of more drug metabolism studies on black patients. Journal of the National Medical Association, 2004, 96, 556-7.	0.6	1
704	CYP2D6 and CYP2C19 in Papua New Guinea: High frequency of previously uncharacterized CYP2D6 alleles and heterozygote excess. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 310-9.	0.4	10
706	Variants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study. International Journal of Molecular Epidemiology and Genetics, 2013, 4, 35-48.	0.4	6
707	Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective. Indian Journal of Medical Research, 2014, 139, 27-65.	0.4	24
709	MET inhibitors in combination with other therapies in non-small cell lung cancer. Translational Lung Cancer Research, 2012, 1, 238-53.	1.3	21
710	Genetic polymorphisms and phenotypic analysis of drug-metabolizing enzyme CYP2C19 in a Li Chinese population. International Journal of Clinical and Experimental Pathology, 2015, 8, 13201-8.	0.5	12
711	Development of a High-Resolution Melting Analysis Method for CYP2C19*17 Genotyping in Healthy Volunteers. Avicenna Journal of Medical Biotechnology, 2016, 8, 193-199.	0.2	6
712	Single Nucleotide Polymorphisms and the Central Nervous System: Potential Biomarkers in Identifying Suicide Risk. Innovations in Clinical Neuroscience, 2017, 14, 21-24.	0.1	1
715	The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles. Pharmaceutics, 2021, 13, 1961.	2.0	20
716	Antiplatelet Therapy for Atherothrombotic Disease in 2022â€”From Population to Patient-Centered Approaches. Frontiers in Cardiovascular Medicine, 2022, 9, 805525.	1.1	12
717	The Clinical Features of In-Hospital Recurrence in Acute Ischaemic Stroke Patients over Time: A Real-World Observation at a Single Center. Brain Sciences, 2022, 12, 123.	1.1	3
718	Cytochrome P450 3A5 polymorphism affects the metabolism of sorafenib and its toxicity for hepatocellular carcinoma cells <i>in vitro</i> . Human and Experimental Toxicology, 2022, 41, 096032712210802.	1.1	2
720	The Efficacy and Safety of Cilostazol vs. Aspirin for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis. Frontiers in Neurology, 2022, 13, 814654.	1.1	1
721	Coil Embolization of Unruptured Cerebral Aneurysms Using Stents in Small Arteries Less Than 2 mm in Diameter. Neurosurgery, 2022, 90, 538-546.	0.6	2
722	Selective Serotonin Reuptake Inhibitor Pharmacokinetics During Pregnancy: Clinical and Research Implications. Frontiers in Pharmacology, 2022, 13, 833217.	1.6	8
723	CYP2C19 plays a major role in the hepatic <i>N</i> -oxidation of cotinine. Drug Metabolism and Disposition, 2022, , DMD-AR-2021-000624.	1.7	4
724	Impact of polymorphisms of pharmacokineticsâ€”related genes and the inflammatory response on the metabolism of voriconazole. Pharmacology Research and Perspectives, 2022, 10, e00935.	1.1	8
725	Asiaâ€”Inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo. Clinical Pharmacology and Therapeutics, 2023, 113, 298-309.	2.3	7

#	ARTICLE	IF	CITATIONS
727	Evaluation of a six-probe cocktail (caffeine, tolbutamide, omeprazole, dextromethorphan, midazolam,) Tj ETQq0 0 0 rgBT /Overlock 10 T after a single oral dosing in healthy Chinese volunteers. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2022, 395, 815-826.	1.4	1
729	Pharmacogenetics of Drug Disposition. , 0, , 385-421.		0
731	Polymorphisms. , 2013, , 21-33.e2.		1
732	Integration of a Physiologically Based Pharmacokinetic and Pharmacodynamic Model for Tegoprazan and Its Metabolite: Application for Predicting Food Effect and Intra-gastric pH Alterations. <i>Pharmaceutics</i> , 2022, 14, 1298.	2.0	4
733	Effects of Simvastatin on the Metabolism of Vonoprazan in Rats Both in vitro and in vivo. <i>Drug Design, Development and Therapy</i> , 0, Volume 16, 1779-1789.	2.0	2
734	Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44. <i>Cancers</i> , 2022, 14, 3444.	1.7	6
735	Pharmacogenetics of Antiplatelet Therapy. <i>Annual Review of Pharmacology and Toxicology</i> , 2023, 63, 211-229.	4.2	9
736	CYP2C19 genotype-guided antithrombotic treatment versus conventional clopidogrel therapy in peripheral arterial disease: study design of a randomized controlled trial (GENPAD). <i>American Heart Journal</i> , 2022, 254, 141-148.	1.2	6
737	Prescription Advice Based on Data of Drug-Drug-Gene Interaction of Patients with Polypharmacy. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 15, 765-773.	0.4	0
739	Cytochrome P450 enzymes in the pediatric population: Connecting knowledge on P450 expression with pediatric pharmacokinetics. <i>Advances in Pharmacology</i> , 2022, , 365-391.	1.2	1
740	Therapeutic Drug Monitoring and Toxicology: Relevance of Measuring Metabolites. , 2022, , 197-232.		0
741	Pharmacokinetic Herb-Drug Interactions of Glipizide with <i>Andrographis paniculata</i> (Burm. f.) and <i>Andrographolide</i> in Normal and Diabetic Rats by Validated HPLC Method. <i>Molecules</i> , 2022, 27, 6901.	1.7	7
742	Antileishmanial Activity of 4,8-Dimethoxynaphthalenyl Chalcones on <i>Leishmania amazonensis</i> . <i>Antibiotics</i> , 2022, 11, 1402.	1.5	6
744	Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. <i>Clinical Therapeutics</i> , 2022, 44, 1604-1623.	1.1	17
745	Efficacy, Safety, Tolerability, and Pharmacokinetics of MMV390048 in Acute Uncomplicated Malaria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2023, 108, 81-84.	0.6	4
746	A Systematic Review of Clopidogrel Resistance in Vascular Surgery: Current Perspectives and Future Directions. <i>Annals of Vascular Surgery</i> , 2023, 91, 257-265.	0.4	4
747	Personalizing atomoxetine dosing in children with ADHD: what can we learn from current supporting evidence. <i>European Journal of Clinical Pharmacology</i> , 0, , .	0.8	0
748	3D-QSAR Studies, Molecular Docking, Molecular Dynamic Simulation, and ADMET Proprieties of Novel Pteridinone Derivatives as PLK1 Inhibitors for the Treatment of Prostate Cancer. <i>Life</i> , 2023, 13, 127.	1.1	7

#	ARTICLE	IF	CITATIONS
749	Review Article: Genetic Polymorphism Studies and Insurgence of Human Genetic Diseases. , 2022, 1, 161-178.		0
750	Correlation analysis and prognostic value of miR-29a-3p expression and CYP2C19 genotypes in exfoliated cells from tongue coating of patients with gastroesophageal reflux disease. Genes and Genomics, 0, , .	0.5	0
751	Long-term use of clopidogrel versus ticagrelor or prasugrel in patients with acute myocardial infarction after percutaneous coronary intervention. PLoS ONE, 2023, 18, e0278993.	1.1	1
752	Reflections on the Lack of Consideration of Ethnic Ancestry to Stratify Clozapine Dosing. Psychiatry Investigation, 2023, 20, 183-195.	0.7	14
753	Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease. Nature Communications, 2023, 14, .	5.8	10
754	Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines. Current Neurology and Neuroscience Reports, 2023, 23, 235-262.	2.0	6
755	Evaluation of the cytochrome <sc>P450 2C19</sc> and <sc>3A4</sc> inhibition potential of the complement factor 5a receptor antagonist <sc>ACT</sc> â€1014â€6470 in vitro and in vivo. Clinical and Translational Science, 0, , .	1.5	0
756	Assessment of Platelet Function by Automated Light Transmission Aggregometry. Methods in Molecular Biology, 2023, , 611-625.	0.4	0
759	Pharmacogenomics in gastroenterology. , 2023, , 271-297.		0
766	Pharmacogenetics: A New Approach for the Selection of the Right Drug. , 2023, , 77-98.		0
767	The Prevalence of Allele Frequencies of CYP2C19 Polymorphisms of Clinically Important Drug-Metabolizing Enzymes CYP2C19 in Moldova Healthy Population. IFMBE Proceedings, 2024, , 392-401.	0.2	0
770	Pharmacogenomics of Drug-Metabolizing Enzymes. , 2023, , 35-60.		0